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ABSTRACT 
 
David Kashatus: An investigation of the function of IκB family member Bcl-3 and its role in 
oncogenesis 
(Under the direction of Albert S. Baldwin Jr.) 
 
 
Bcl-3 was originally identified as a protein that is highly expressed in certain B-cell 
lymphomas harboring a 14;19 translocation, and more recent evidence indicates that its 
expression is characteristic of a large number of human cancers. A member of the IκB family 
of NF-κB inhibitors, Bcl-3 interacts with NF-κB dimers containing p50 or p52 and promotes 
transcription of a subset of NF-κB dependent genes.  However, neither the role of Bcl-3 in 
oncogenesis, nor its role in normal physiology, has been clearly defined. 
My research has focused on elucidating the function of Bcl-3 in the context of DNA 
damage signaling in order to gain insight into its physiological and pathological roles.  
Experiments presented here indicate that Bcl-3 is inducible by DNA damage and is required 
for the induction of Hdm2 gene expression and the suppression of persistent p53 activity. 
Furthermore, constitutive expression of Bcl-3 suppresses DNA damage-induced p53 
activation and inhibits p53-induced apoptosis through a mechanism that is at least partly 
dependent on the upregulation of Hdm2. The results provide insight into a mechanism 
whereby altered expression of Bcl-3 leads to tumorigenic potential. Since Bcl-3 is required 
for germinal center formation, these results further indicate that Bcl-3 may play a critical in 
the B-cell maturation process by suppressing p53-dependent apoptosis in response to somatic 
hypermutation and class switch recombination.  
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  As aberrant expression of Bcl-3 has been found in an increasing number of human 
cancers, my second project set out to investigate whether Bcl-3 plays a role in hepatocellular 
carcinoma (HCC).  The data indicate that nuclear staining of Bcl-3 is present in a high 
percentage of primary HCC tumors compared to adjacent normal tissue.  Furthermore, 
western blot analysis indicates that high Bcl-3 expression correlates positively with 
expression of Hdm-2.  These data suggest that Bcl-3 may play a causal role in HCC and 
indicate that it may be functioning through inhibition of p53. 
 Collectively, the work described here proposes a novel function for the oncoprotein 
Bcl-3 that provides insight into both its normal and oncogenic roles and provides further 
evidence for the expanding role of Bcl-3 in human cancer. 
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INTRODUCTION 
 
 The genomes of mammalian cells are constantly exposed to a wide variety of insults 
from both exogenous and endogenous sources.  In order to maintain cell viability and to 
ensure the proper formation and maintenance of complex tissues, evolution has provided 
cells with numerous mechanisms to repair the damage incurred, when possible, and to 
minimize the deleterious effects the genetic lesions may have on cellular function.  Failure of 
these protective mechanisms can lead to the accumulation of mutations of genes encoding 
key components of the cellular machinery, mutations that can compromise cellular function 
and ultimately result in disease, most notably, cancer. 
 Recent years have seen major progress in our understanding of how cells respond to 
genomic insults.  A variety of biochemical pathways have been identified that can recognize 
DNA damage and elicit complex responses leading to repair of damaged DNA, arrest of the 
cell cycle, and when warranted, elimination of damaged cells through the process of 
programmed cell death.  Each of these pathways involves the coordinated interaction of 
numerous proteins and integrates multiple signals to arrive at the appropriate cellular 
response.  While our understanding of these pathways has grown significantly in recent 
years, a complete understanding of these complex processes remains incomplete. 
 The p53 tumor suppressor protein has been identified as a critical mediator of the 
cell’s response to DNA damage.  Often referred to as the guardian of the genome, p53 is 
activated by a wide variety of genomic insults and its activation leads to critical cell fate 
decisions, including cell cycle arrest and apoptosis (Vousden and Lu 2002).  A sequence 
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specific transcription factor, activated p53 binds to the promoter regions of numerous genes 
including the cell cycle inhibitor p21 and pro-apoptotic proteins Bax, Noxa and Puma to 
induce their transcription.  In a poorly understood way, the cell then integrates the multiple 
signals initiated by p53 to execute the appropriate response (Oren 2003). 
 Another transcription factor that plays an important, though poorly understood, role 
in response to genomic insults is NF-κB.  The role of NF-κB in mediating innate and 
adaptive immunity has been studied in great depth and the molecular details of its response to 
cytokines, growth factors and various infectious agents has been increasingly well defined in 
recent years (Ghosh and Karin 2002).  However, the influence of NF-κB in a much wider set 
of cellular processes has also been emerging, providing a wealth of open questions and 
research opportunities for scientists interested in NF-κB. 
 The NF-κB family consists of five mammalian homologues (p65, RelB, C-Rel, p50 
and p52) which can homo- or hetero-dimerize to form active transcriptional complexes.  NF-
κB is normally maintained in a latent state through its interaction with its inhibitor IκB.  
There are at least six members of the IκB family, including IκBα, IκBβ, IκBε, Bcl-3, p100 
and p105, each of which can interact with NF-κB through its internal ankyrin repeat domain 
(Hayden and Ghosh 2004).  Traditionally, much of the research focus has been on so-called 
classical NF-κB, which consists of a heterodimer of the p50 and p65 subunits, as this dimer 
plays a dominant role in many of the well-defined pathways of NF-κB activation.  However, 
as the far-reaching influence of NF-κB has begun to be uncovered, so to have the roles of 
many of the other NF-κB and IκB family members. 
 Bcl-3 is one of the factors whose cellular function has only begun to emerge.  
Originally cloned as a breakpoint junction in certain B-cell chronic lymphocytic leukemias 
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(McKeithan et al. 1987), Bcl-3 is unique among IκB family members in that, unlike the other 
IκBs that bind to NF-κB dimers and sequester them in the cytoplasm, Bcl-3 is predominantly 
nuclear, and has a C-terminal transactivation domain.  Shortly after it was cloned, Bcl-3 was 
shown to preferentially bind to p50 and p52 homodimers and was subsequently shown to 
promote transactivation at NF-κB dependent promoters (Ohno et al. 1990; Franzoso et al. 
1992; Franzoso et al. 1993; Nolan et al. 1993). 
 In addition to its apparent role in B-CLL, Bcl-3 has been shown to be present at high 
levels in the nuclei of numerous solid tumors (Cogswell et al. 2000; Thornburg et al. 2003), 
suggesting an oncogenic function.  Additionally, sporadic evidence has hinted at a role for 
Bcl-3 in the cellular response to DNA damage (Boulton et al. 2002; Rocha et al. 2003; 
Watanabe et al. 2003).  This evidence has prompted a more thorough investigation into the 
specific function of Bcl-3, which is the focus of this doctoral dissertation. 
 As described earlier, DNA damage signals lead to the activation of the transcription 
factor p53.  The work described here identifies Bcl-3 as a critical factor in mediating this 
response.  In cells expressing low basal levels of Bcl-3, DNA damage signals result in a 
transient increase in Bcl-3 protein levels, suggesting it may have an important role in the 
damage response.  Intriguingly, when expressed at higher levels, Bcl-3 inhibits DNA 
damage-mediated stabilization of p53 and leads to protection against p53-dependent 
apoptosis.  Additionally, loss of Bcl-3 leads to an enhanced p53 response and subsequent 
sensitization to DNA-damage induced apoptosis.  The mechanism of this inhibition of p53 is 
at least partly through Bcl-3 mediated induction of the inhibitor of p53, mdm2. 
 These findings provide insight into a novel mode of regulation of the critically 
important tumor suppressor p53.  Importantly, they may also shed light on the still poorly 
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understood role that the NF-κB family plays in response to genomic damage.  Finally, these 
results allow us to begin to better understand both the normal physiological function of Bcl-
3, as well as its potential oncogenic function.  This understanding will offer new tools to fight 
the growing number of cancers that over-express Bcl-3.  
 
I. NF-κB 
 
The NF-κB Family 
 NF-κB was originally identified in 1986 as a nuclear factor that bound to an enhancer 
element in the gene encoding immunoglobulin (Ig)κ light-chain and was thought to be 
specifically confined to B-cells (Sen and Baltimore 1986).  Investigation of this factor 
quickly revealed however that its expression is in fact ubiquitous, though it is normally 
retained in the cytoplasm in a latent state through specific interactions with a family of 
inhibitors collectively known as IκB (Haskill et al. 1991; Beg et al. 1992).  Subsequent 
studies of NF-κB showed that it is a member of a family of dimeric transcription factors of 
which there are five known mammalian homologues (p65, RelB, c-Rel, p50 and p52).   
These proteins share a highly conserved 300 amino acid sequence in the N-terminus known 
as the Rel homology domain (RHD), which is composed of two immunoglobulin-like 
domains (Ghosh et al. 1990; Nolan et al. 1991).  The RHD is critical for dimerization and 
binding to the consensus κB binding sequence, GGGRNNYYCC (R = purine, Y = 
pyrimidine and N = any base).  Additionally, the RHD mediates the interaction between NF-
κB and its inhibitor IκB (Hayden and Ghosh 2004). 
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 The use of different dimer combinations allows NF-κB to elicit a diverse array of 
transcriptional responses as different dimers exhibit different binding affinities to NF-κB 
consensus sequences (Fujita et al. 1992; Kunsch et al. 1992). Additionally, the p65, c-Rel and 
RelB subunits each contain two potent acid-rich transactivation domains of 30 amino acids 
(TA1 and TA2) in their C-terminus (Schmitz et al. 1994). These domains promote 
transcription through the recruitment of transcriptional co-activators, a process that seems be 
dependent on specific post-translational modifications such as phosphorylation and 
acetylation (Gerritsen et al. 1997; Zhong et al. 1998; Chen et al. 2001; Zhong et al. 2002).  
Notably, p50 and p52, which are initially formed as 105 and 100 kD precursors (p105, p100) 
respectively, lack such transactivation domains and consequently require either dimerization 
to one of the other family members, or an interaction with IκB family member Bcl-3, to form 
transcriptionally active complexes. 
 
Regulation of NF-κB 
 As a potent transcriptional activator with a diverse set of target genes, NF-κB is 
tightly regulated through a variety of mechanisms.  The best-characterized mechanism of 
regulation involves the interaction between NF-κB dimers and members of the IκB family of 
inhibitors.  There are at least six mammalian members of the IκB family, IκBα, IκBβ, IκBε, 
Bcl-3 and the NF-κB precursor proteins p100 and p105.  IκB proteins each contain an 
internal ankyrin repeat domain (ARD) consisting of six or seven 33 amino acid ankyrin 
repeats.  Structural and functional studies have revealed that the ARD mediates tight binding 
between IκB and NF-κB dimers (Hatada et al. 1992).   Importantly, many of the IκB proteins 
contain a potent nuclear export sequence and mask the nuclear localization sequence present 
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in the RHD of most NF-κB proteins (Huxford et al. 1998; Malek et al. 1998).  Thus, NF-
κB/IκB complexes are maintained in the cytoplasm, where NF-κB is unable to promote 
transcription of its target genes. 
  Although activation of NF-κB can occur in a number of different ways, disruption of 
the NF-κB/IκB complex is essential as it allows NF-κB to translocate to the nucleus and bind 
to target gene promoters.  The most common way that this occurs is through the regulated 
proteosomal degradation of IκB following stimulus specific phosphorylation on two key 
serine residues and subsequent polyubiquitination (Chen et al. 1995; Scherer et al. 1995).  
For example, IκBα, which binds to a number of NF-κB dimers including the most abundant 
p65/p50 heterodimer, is inducibly phosphorylated on serines 32 and 36 following stimulation 
of cells by TNFα or other pro-inflammatory cytokines (Brown et al. 1995; DiDonato et al. 
1996).  This phosphorylation results in the recruitment of a ubiquitin ligase complex 
containing the E3 ubiquitin ligase β-TrCP which covalently attaches a poly-ubiquitin chain to 
lysines 21 and 22 of IκBα (Yaron et al. 1998).  Poly-ubiquitination of IκBα leads to its 
degradation by the 26S proteosome, allowing the freed NF-κB dimers to accumulate in the 
nucleus and activate transcription. 
 Similarly, stimulation of cells with lymphotoxin-β leads to activation of RelB/p100 
NF-κB dimers through phosphorylation of serines 927 and 932 in the C-terminus of p100.  
This phosphorylation leads to poly-ubiquitinaton and degradation of the ankyrin repeat-
containing c-terminus, resulting in RelB/p52 dimers, which can then translocate to the 
nucleus and activate transcription (Senftleben et al. 2001; Lang et al. 2003). 
 The key player in mediating the disruption of the NF-κB/IκB complex, and thus a key 
regulator of NF-κB activity, is the IκB kinase complex (IKK).  First identified in 1996 as a 
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700-900 kD complex, the various components of IKK were subsequently cloned and shown 
to consist of two kinases, IKKα and IKKβ, that share 52% sequence identity, and a 
regulatory subunit IKKγ/NEMO (Chen et al. 1996; Lee et al. 1997).  IKKα and IKKβ are 
each characterized by an N-terminal kinase domain, a C-terminal helix-loop-helix domain, 
and a leucine zipper domain (DiDonato et al. 1997; Zandi et al. 1997).  IKKγ, which is 
unrelated to IKKα and IKKβ, contains a C-terminal zinc finger-like domain, a leucine zipper, 
and N- and C-terminal coiled-coil domains (Yamaoka et al. 1998).  IKK phosphorylates 
members of the IκB family on multiple residues and has other targets as well, including p65. 
 Kinase activity of IKK requires dimerization, which is mediated by the leucine zipper 
domains, and available data indicate that heterodimers of IKKα and IKKβ are predominant 
(Mercurio et al. 1997).  While knockout experiments indicate some overlap in function, the 
two kinases exhibit different specificities for the different IκB family members.  As such, 
IKKβ seems to be the dominant kinase for IκBα, while IKKα is dominant in the 
lymphotoxin-β mediated phosphorylation of p100 (Li et al. 1999a; Li et al. 1999b; Tanaka et 
al. 1999; Senftleben et al. 2001).  IKKγ, while lacking intrinsic kinase activity, is a key 
structural component of IKK whose presence is required for the kinase activity of the 
complex (Rothwarf et al. 1998; Rudolph et al. 2000). 
 Ultimately, if not exclusively, the numerous signals that lead to activation of NF-κB 
converge on the IKK complex leading to its phosphorylation of IκB proteins.  The 
subsequent ubiquitination and degradation of IκB and release of NF-κB is the key regulatory 
step allowing NF-κB to activate its target genes. 
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Biological Function of NF-κB 
 The complex regulation of NF-κB activity is critical considering the wide variety of 
biological processes in which it is involved.  Much of what we know about the biological 
roles of the NF-κB and IκB family members comes from analyses of the various knock-out 
mice that have been generated for these factors.  The data confirm a crucial role for NF-κB in 
immune function and also highlight the important roles for NF-κB in other cellular and 
physiological processes. 
 The p65 knockout mice exhibit embryonic lethality at day E15/16 due to massive 
liver apoptosis (Beg et al. 1995b).  This apoptosis was shown to be dependent on TNFα 
signaling as this lethality could be rescued by crossing the mice with either the TNFα or 
TNFR knockout mice (Doi et al. 1999; Alcamo et al. 2001).  These double knockout mice 
exhibit increased susceptibility to bacterial infection, confirming a role for p65 in innate and 
adaptive immunity.  Further, fibroblasts generated from the p65 null embryos displayed a 
loss of induction of known NF-κB target genes following induction with TNFα, confirming 
the critical importance of the p65 subunit for NF-κB activity (Beg et al. 1995b). 
Genetic analysis of the other NF-κB subunits also highlights the role of the NF-κB 
family in immune function.  The p50 knockout mouse exhibits decreased immunoglobulin 
production and defective humoral immune responses (Sha et al. 1995).  The p52 knockout 
mice fail to develop normal B-cell follicles and have defects in their splenic 
microarchitecture and Peyer’s patch development (Caamano et al. 1998; Franzoso et al. 
1998; Paxian et al. 2002).  RelB deficient mice exhibit decreased NF-κB activity in the 
thymus and spleen and have increased inflammatory infiltration in multiple organs and 
deficits in adaptive immunity (Weih et al. 1995).  Finally, c-Rel deficient mice fail to 
 9
generate an effective humoral immune response and their peripheral B and T cells fail to 
respond to mitogenic stimuli (Kontgen et al. 1995). 
 Knockout mice have also been generated for many of the IκB family members and 
suggest some overlap, but not redundancy, in function.  IκBα mice exhibit increased, but not 
constitutive, basal NF-κB activity (Beg et al. 1995a; Klement et al. 1996).  Furthermore, 
analysis of cells lacking IκBβ and IκBε, and double and triple knockouts of all three have 
revealed that while all three can effectively inhibit NF-κB function, the difference in their 
activity seems to be primarily due to differences in the rate of their degradation and re-
synthesis (Hoffmann et al. 2002).  Notably, IκBα is the only IκB known to be 
transcriptionally regulated by NF-κB and thus it provides critical negative feedback 
regulation following NF-κB activation.  The knockout of IκB family member Bcl-3 also 
reveals an important role in immune function and will be discussed in detail later. 
 Genetic analysis of the NF-κB and IκB family members has revealed an important 
role for this family in all aspects of immune function and in addition to a potentially much 
broader role regulating apoptosis.  The breadth of its influence has only increased since these 
analyses were performed.  As research has progressed, myriad pathways have been found to 
activate NF-κB resulting in a variety of biological responses.  We turn our attention to the 
pathways leading to NF-κB activation, emphasizing DNA damage, a poorly understood 
aspect of NF-κB biology and the focus of this dissertation. 
 
Signaling Pathways to NF-κB. 
 The most intensely studied pathway leading to NF-κB activation has been the tumor 
necrosis factor (TNF) signaling pathway.  The TNF superfamily consists of at least 19 
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soluble ligands with 29 known receptors and performs multiple roles in the innate and 
adaptive immune response (Aggarwal 2003).  Of these family members, TNFα has been the 
most widely studied, and has become the canonical model for activation of NF-κB.   Upon 
binding to the TNF receptor (TNFR), TNFα induces receptor dimerization and subsequent 
recruitment of a host of adaptor molecules including the TNFR associated death domain 
protein TRADD.  Ultimately, TRADD recruitment leads to activation of numerous effector 
molecules including the pro-apoptotic Caspase 8 and the c-Jun N-terminal Kinase (JNK).  In 
addition, through interactions with the TNFR associated factor (TRAF) family of proteins, 
the IKK signaling complex is recruited to the receptor and activated (Aggarwal 2003). 
 While the activation of caspase 8 intitiates a pro-apoptotic signaling cascade, 
activation of IKK leads to rapid phosphorylation of IκBα and subsequent release of the 
p65/p50 NF-κB heterodimer.  This activation of NF-κB leads to the rapid induction of anti-
apoptotic genes such as cIAP1/2 and Bcl-XL and ultimately the termination of the apoptotic 
response (Wang et al. 1998).  In addition, NF-κB activation leads to induction of pro-
inflammatory cytokines such as IL-6 and TNF, which promote an inflammatory response, 
and manganese superoxide dismutase (MnSOD), which scavenges free radicals and 
potentiates the JNK response (Collart et al. 1990; Shimizu et al. 1990; Jones et al. 1997; 
Sakon et al. 2003). 
 The understanding of the TNF pathway has revealed a clear role for canonical NF-κB 
(ie- p65/p50) in the regulation of apoptosis.  While much of this knowledge can be extended 
to other NF-κB inducing pathways, the complexity of the signaling urges caution.  As the 
wealth of research on NF-κB has shown, the cellular context and use of different arms of the 
NF-κB signaling pathway can lead to different outcomes. 
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 An alternative pathway to NF-κB discussed earlier is that downstream of the 
Lymphotoxin-βR or BAFF-R.  Upon ligand activation, these receptors recruit factors that, in 
a still undefined way, lead to activation of the NF-κB inducing kinase (NIK), which 
phosphorylates and activates IKKα.  IKKα then phosphorylates p100, leading to its 
processing into p52, allowing p52/RelB dimers to enter the nucleus and activate target genes, 
including certain chemokines involved in secondary lymphoid organogenesis (Senftleben et 
al. 2001). 
 Another important NF-κB pathway is downstream of the Toll-like receptors (TLR).  
TLRs are evolutionarily conserved pattern recognition receptors that interact with distinct 
pathogen-associated patterns present on various microbes and elicit a powerful innate 
immune response.  TLRs can bind to diverse ligands such as bacterial associated 
Lipopolysaccharide (LPS), viral associated dsRNA and non-methylated CpG DNA.  Upon 
activation, these receptors recruit adaptors, including MyD88, and other effector molecules, 
which results in the activation of transcription factors AP-1, IRF3 and, through activation of 
IKK, NF-κB.  In the context of TLR signaling, NF-κB activation leads to the induction of a 
set of genes, including pro-inflammatory cytokines, important for recruiting immune cells 
involved in combating the infection (Janeway and Medzhitov 2002). 
 The anti-apoptotic effects of NF-κB have also been shown to be important in adaptive 
immunity.  As such, NF-κB is induced in both B and T-cells following activation of the B-
cell receptor (BCR) and T-cell receptor (TCR), respectively, to allow for antigen specific 
proliferation and maturation of lymphocytes into effector cells.  The details of NF-κB 
activation by BCR and TCR are less well understood, but are thought to involve recruitment 
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of IKK to the immunological synapse and the activity of certain key tyrosine kinases such as 
ZAP70 (Ruland and Mak 2003). 
 Each of the pathways discussed thus far involves activation of NF-κB through the 
recruitment of IKK to a trans-membrane receptor complex followed by release of NF-κB to 
the nucleus.  The differences in the responses to these diverse initiating signals is likely 
mediated by the timing of activation, the different IKK complexes that are formed at the 
receptor leading to different IKK activities (ie- TNF vs LT-β), and the interactions of NF-κB 
with the other signaling pathways downstream of these receptors.  Activation of NF-κB by 
cell stresses, such as DNA damage, therefore presents a unique challenge in that the 
paradigm of receptor-mediated IKK activation that has been established does not apply.  
Because of this, and other factors, our knowledge of this important aspect of NF-κB 
signaling has lagged. 
 
DNA damage signaling to NF-κB 
 Given the ability of NF-κB to induce anti-apoptotic genes, and the use of DNA 
damaging therapeutic agents to treat various cancers, a complete understanding of how these 
agents induce NF-κB and the physiological consequences of that induction are of the utmost 
importance.   It was recognized early on that DNA damage is able to activate NF-κB (Brach 
et al. 1991) however, discrepancies in the systems used to study this phenomenon have 
resulted in inconsistent data and an unclear picture of the molecular events leading to NF-κB 
activation and the subsequent cellular response. 
Inducers of DNA double strand breaks, including ionizing radiation and the 
topoisomerase inhibitor camptothecin, have been shown to induce NF-κB in a process 
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requiring the protein ataxia-telangiectasia mutated (ATM) (Li et al. 2001).  One report 
showed that treatment of cells with topoisomerase inhibitors results in activation of IKK in a 
process dependent on the zinc finger domain of IKKγ (Huang et al. 2002).  More recent 
studies have shown that induction of DNA double strand breaks leads to ATM mediated 
phosphorylation of IKKγ on serine 85, leading to its sumoylation and subsequent nuclear 
export.  In the cytoplasm, sumoylated IKKγ then causes the activation of IKK in a manner 
dependent on the protein ELKS (ADD REF, WU, 2006, Science).  Other studies have shown 
that the protein RIP is required for activation of IKK in response to DNA damage, but how 
this requirement relates to the role of IKKγ sumoylation is unclear (Hur et al. 2003). 
NF-κB is also activated by UV-C irradtiation, which results in several types of DNA 
lesions, including pyrimidine dimers.  NF-κB activation following UV-C treatment has been 
shown to be independent of IKK activation and IκBα serine 32/36 phosphorylation, but may 
require activation of the p38 MAP Kinase and subsequent activation of casein kinase 2 
(CK2) (Li and Karin 1998; Kato et al. 2003; Tergaonkar et al. 2003).  CK2 phosphorylation 
of serine residues on the C-terminus of IκBα is proposed to then mediate the release of 
p65/p50 heterodimers from IκBα (Kato et al. 2003).  Similar mechanisms of NF-κB 
activation have been proposed in cells treated with doxorubicin, and it remains unclear 
whether the initiating signal is the DNA damage itself or perhaps reactive oxygen species 
that are generated (Tergaonkar et al. 2003; Zhang and Chen 2004). 
The activation of NF-κB by DNA damage is likely also influenced by other damage-
induced signaling pathways.  For example, it has been shown that p53, which is induced by 
DNA damage, can induce NF-κB activation, and that this induction is required for p53-
mediated apoptosis (Ryan et al. 2000).  These data conflict with other reports that suggest 
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that the activity of p53 and NF-κB is mutually antagonistic due to competition for 
transcriptional co-activators, and that IKK activation leads to inhibition of p53 through 
induction of the p53 inhibitor mdm2 (Webster and Perkins 1999; Tergaonkar et al. 2002). 
It is also unclear whether NF-κB is always anti-apoptotic when activated by DNA 
damage.  In addition to the report of NF-κB being required for p53-dependent apoptosis, 
other recent studies have shown that doxorubicin- or UV-C-induced NF-κB can inhibit 
transcription of anti-apoptotic genes through the recruitment of histone deacetylases to their 
promoters (Campbell et al. 2004).  These studies underscore the importance of understanding 
the role of NF-κB in mediating the DNA damage response.  A number of current cancer 
therapies involve DNA-damaging chemotherapeutics in combination with inhibitors of NF-
κB, under the assumption that induction of NF-κB by these drugs will provide the tumor 
cells with protection against apoptosis (Orlowski and Baldwin 2002).  If NF-κB is in fact 
pro-apoptotic in certain circumstances, these treatments may have undesirable effects. 
Additionally, many of the inhibitors of NF-κB currently in therapeutic use may be 
limited in that they target key molecules in the canonical NF-κB pathway, such as IKK 
(Orlowski and Baldwin 2002).  Given the available data, it is unclear whether this strategy 
will target the appropriate NF-κB pathways as other non-traditional NF-κB family members 
might also play an important role in oncogenesis.  One family member in particular whose 
role in oncogenesis has not been well defined is Bcl-3.  A number of recent reports have 
suggested that Bcl-3 may be involved in the DNA damage response (Boulton et al. 2002; 
Rocha et al. 2003; Watanabe et al. 2003), perhaps providing an additional link between the 
NF-κB family and DNA damage.  However, the nature of this role has remained unclear. 
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II. Bcl-3 
 
Bcl-3 function 
 Bcl-3 was originally identified by molecular cloning of the t(14,19) breakpoint 
junction occurring in a subset of B-cell chronic lymphocytic leukemias (B-CLL) (McKeithan 
et al. 1987).  This translocation placed the Bcl-3 gene downstream of a strong Ig enhancer 
element, which resulted in high levels of expression of Bcl-3 protein in these cells.  Sequence 
analysis revealed Bcl-3 to be a 446 amino acid protein with a proline rich N-terminus and 
proline/serine rich C-terminus flanking 7 internal ankyrin repeats (Ohno et al. 1990).  
Expression of Bcl-3 is high in both the liver and spleen, with lower expression in the heart, 
skeletal muscle, lung kidney and testes (Nolan et al. 1993).  Further analysis of its expression 
in mouse B-cell lines shows that its levels are highest at a developmental stage just prior to Ig 
switch (Bhatia et al. 1991). 
Early biochemical analyses revealed that Bcl-3 bound tightly to p50 and p52 
homodimers both in vitro and in vivo (Wulczyn et al. 1992; Bours et al. 1993).  An early 
model of Bcl-3 activity suggested that it aids in NF-κB dependent transcription through its 
ability to remove inhibitory p50 homodimers from promoters to allow activating p50/p65 
heterodimers to bind (Franzoso et al. 1992; Hatada et al. 1992; Wulczyn et al. 1992).  Further 
analysis however showed that Bcl-3 could play a more direct role in transcription when it 
was shown that Bcl-3, in complex with p52 homodimers, could directly activate transcription 
from NF-κB dependent promoters through two cooperating transactivation domains located 
N- and C-terminal to its ankyrin repeat domain (Bours et al. 1993).  In support of the latter 
hypothesis, it was shown that Bcl-3 co-localizes with p50 at sites of active transcription in 
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the nucleus (Zhang et al. 1994).  Further, it was shown that Bcl-3 is extensively 
phosphorylated on its C-terminus, and that this phosphorylation is critical for allowing 
p52/Bcl-3 complexes to bind DNA (Bundy and McKeithan 1997). 
 
Bcl-3 Biology 
While these early biochemical analyses revealed important aspects of Bcl-3 function, 
they shed little light on how Bcl-3 was regulated and what genes it may regulate.  One early 
report suggested that Bcl-3 expression is induced by NF-κB and NF-κB-dependent stimuli, 
although it is unclear whether this occurs in all cell types (Bhatia et al. 1991).  More recently, 
it has been shown that Bcl-3 is induced by Interleukin-1 in chondrocytes and synovial 
fibroblasts to activate transcription of the matrix metalloproteinase 1 (MMP1) gene (Elliott et 
al. 2002).  It has also been shown that Bcl-3/p52 complexes can induce transcription of the 
anti-apoptotic Bcl-2 gene, as well as the cell cycle protein cyclin D1 (Westerheide et al. 
2001; Viatour et al. 2003).  Activation of target genes by Bcl-3 is likely accomplished 
through its interactions with histone acetylases such as Tip60 and with general transcription 
factors such as TFIIB, TBP and TFIIA, although the molecular details of these interactions 
have yet to be worked out (Na et al. 1998; Dechend et al. 1999). 
Somewhat surprisingly, Bcl-3 has also been shown to be able to directly inhibit 
transcription at certain promoters.  For example, it has been shown that interleukin 10 (IL10) 
induces Bcl-3 expression in macrophages and that Bcl-3 directly inhibits LPS-induced TNFα 
production in these cells (Kuwata et al. 2003).  Its ability to interact with the histone 
deacetylase, HDAC1, likely contributes to this activity (Wessells et al. 2004).  Thus, through 
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differential recruitment of co-activators and co-repressors, Bcl-3 can both activate and 
repress transcription of target genes. 
Some functions of Bcl-3 may also be mediated through its interactions with non-NF-
κB related proteins.  For example, Bcl-3 has been shown to interact with the retinoic acid 
receptor (RXR) to activate RXR-induced transcription (Na et al. 1998).  Additionally, Bcl-3 
has been shown to interact with the transcription factor AP1 (Na et al. 1999).  How these 
various interactions contribute to Bcl-3’s biological function is not known. 
Some insight into the biological function of Bcl-3 has been gained from studies of the 
Bcl-3 knockout mouse, which has been generated independently by two different labs.  These 
mice, while developmentally normal, have numerous defects in immune function.  They are 
unable to clear L. monocytogenes and are susceptible to infection by S. pneumoniae.  
Additionally, Bcl-3 knockout mice fail to generate antigen-specific antibodies and have 
abnormal spleen development, including the inability to form germinal centers (Franzoso et 
al. 1997; Schwarz et al. 1997).  Consistent with the high levels of expression in lymphocytes, 
this phenotype suggests a critical role for Bcl-3 in immune cell function. 
 
Bcl-3 in oncogenesis 
In addition to its functions in normal physiology, Bcl-3, when dysregulated, may also 
play a role in certain pathologies, notably, cancer.  Ever since its expression was identified in 
B-CLL, a role for Bcl-3 in human cancer has been proposed.  More recently, high levels of 
Bcl-3 expression have been noted in a number of other cancers.  One survey found Bcl-3 
over-expressed in a high percentage of B- and T-cell lymphomas of various origins, 
including 26% of diffuse large B-cell lymphomas and 23% of all T- and NK-cell lymphomas 
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(Canoz et al. 2004).  Another study showed that Bcl-3 expression was high in a number of 
anaplastic large cell lymphomas (ALCL) (Nishikori et al. 2003). 
In addition to leukemias and lymphomas, Bcl-3 expression is increasingly found in a 
number of solid tumors.  One study has shown that Bcl-3 is found at high levels in the nuclei 
of many breast cancers (Cogswell et al. 2000), and another showed that Bcl-3 is important 
for the development of nasopharyngeal carcinoma (Thornburg et al. 2003).  However, while 
Bcl-3 expression is being found to be characteristic of an increasing number of cancers, the 
data implicating it as a direct causal factor have been limited. 
 The ability of Bcl-3 to activate transcription of genes such as the anti-apoptotic Bcl-2 
and cell cycle activator cyclin D1 has been suggested to contribute to its oncogenicity, but 
direct links from these activities to oncogenesis have not been formally shown.  Bcl-3 has 
also been shown to be required for the estrogen-independent phenotype in certain breast 
cancer cell lines, but again, the mechanism through which this is achieved has been elusive 
(Pratt et al. 2003).  One potential oncogenic role for Bcl-3 that has not been explored in depth 
is its influence on the DNA damage response.  As mentioned earlier, activated p53 has been 
shown to decrease levels of Bcl-3, leading to loss of cyclin D1 expression due to recruitment 
of HDAC1 to p52 homodimers (Rocha et al. 2003).  Bcl-3 has also been shown to interact 
with a novel protein that has 5’ polynucleotide kinase activity, suggesting a potential role in 
DNA repair (Watanabe et al. 2003).  Additionally, a putative orthologue of Bcl-3 was 
identified in C. elegans.  When this orthologue was knocked down by RNAi, these worms 
showed severe defects in the DNA damage response (Boulton et al. 2002). 
 This evidence suggests an uncovered function of Bcl-3 that could potentially be 
important both for its normal role in immune cell function, and its role in oncogenesis.  To 
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begin to uncover that role, it is critical to understand what is already known about how cells 
respond to DNA damage. 
 
III. The DNA damage response  
 
 DNA lesions, from both exogenous and endogenous sources, pose a serious threat to 
the integrity of the genome.  The genetic mutations that result from these lesions have serious 
consequences on cellular function and viability and thus eukaryotic cells have devised 
myriad complex ways of sensing and dealing with this damage.   Years of research in this 
field have revealed many of the molecular details of the cellular DNA damage response, but 
many holes still exist on our knowledge.  While the vast literature prevents a complete 
discussion of these details, it is important to review some of the key aspects of this response, 
including the mechanisms of damage detection, the cell cycle checkpoints and apoptotic 
pathways elicited by the damage sensing factors, and the role of p53 in this response.   
 
DNA Damage Detection 
 Normal DNA metabolism and exposure to environmental factors result in a wide 
variety of chromosomal lesions, and a complex surveillance system exists to recognize these 
many aberrant structures.  In mammals, the current evidence suggests that two key protein 
kinases (ATM and ATR), belonging to the PI3 Kinase family, and four other key gene 
products (RAD17, RAD1, RAD9 and HUS1) are involved in damage recognition and 
initiation of the cellular response (Qin and Li 2003).  ATM (ataxia telagiectasia mutated) 
kinase activity is activated immediately following exposure to ionizing radiation or 
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radiometric drugs and loss of its function results in radio-resistant DNA synthesis and 
erroneous entry into mitosis (Lavin and Shiloh 1997; Canman et al. 1998; Rotman and Shiloh 
1998).  ATM has also been shown to bind directly to DNA double strand break ends (Smith 
et al. 1999).  It has been noted however that AT cells (cells lacking ATM function derived 
from ataxia telangiectasia patients) exhibit little sensitivity to UV radiation or agents that 
block replication (Shiloh 1997).  This observation led to the cloning and identification of 
ATR (ATM and RAD3-related) (Keegan et al. 1996).  ATR seems to respond to a broader 
spectrum of inducers than ATM.  Thus, while ATM seems to exclusively respond to damage 
resulting in DNA double strand breaks, ATR responds to UV radiation, replication block, and 
ionizing radiation (Tibbetts et al. 1999).  Loss of ATR affects the activation of key 
downstream targets such as p53 and leads to defective checkpoint activation following DNA 
damage signals (Cliby et al. 1998; Wright et al. 1998).  Notably, ATM and ATR both 
localize to distinct nuclear foci following the appropriate DNA damage signal, implicating 
them both as key effectors of DNA damage signaling (Andegeko et al. 2001; Cortez et al. 
2001). 
 The activation of ATM and ATR following DNA damage requires the formation of a 
crucial signaling complex consisting of the aforementioned RAD17, RAD9, RAD1 and 
HUS1 proteins.  While the molecular details are still a matter of some debate, following 
DNA damage, RAD9, RAD1 and HUS form a trimeric complex (the 9-1-1 complex) that 
loads onto the DNA at the site of damage and resembles the PCNA trimer (which functions 
as a sliding clamp during DNA replication).  RAD17 is critical for the recruitment of the 9-1-
1 complex and collectively, these factors are referred to as the checkpoint clamp-loader 
proteins (Thelen et al. 1999). 
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 How these proteins all interact to activate downstream targets remains to be fully 
worked out.  As such ATM and ATR-mediated phosphorylation of many of the components 
of the clamp-loader seems to be crucial for complex formation and signal initiation, yet the 
precise order of events and their requirement for initiation of the checkpoint are unclear.  One 
current model suggests that the ATR and ATM kinases and RAD17 colocalize independently 
to sites of DNA damage and interact with the 9-1-1 complex to originate the checkpoint 
signaling process (Qin and Li 2003). 
 BRCA1 and 53BP1 are other factors that play a role in initiating the signaling 
cascades downstream of DNA damage.  While their exact roles are unclear, these factors 
interact with multiple checkpoint and repair factors and loss of their function results in 
multiple checkpoint deficiencies (Joo et al. 2002).  Current research suggests that they may 
function through recruitment of key downstream targets of ATM and ATR. 
 Once activated, ATM and ATR phosphorylate numerous targets to initiate the broad 
response to DNA damage.  Two serine/threonine kinases (CHK1 and CHK2) are primary 
targets for ATM and ATR and are thus classified as effector kinases.  Activation of these 
kinases by ATM and ATR leads to the inititiation of the cell cycle checkpoints and 
phosphorylation of p53, and thus mediate the ultimate decision-making by the affected cell 
(Matsuoka et al. 1998; Liu et al. 2000). 
 
Replication Checkpoints  
 Depending on the cell cycle stage of an affected cell, DNA damage can elicit a 
variety of responses.  When cells in G1 are exposed to DNA damage, a key target of 
ATM/ATR and CHK1/CHK2 is the p53 protein.  p53 is normally kept at low levels through 
 22
its interaction with the E3 ubiquitin ligase mdm2.  Following DNA damage, multiple N-
terminal serines of p53 are targeted either directly by ATM and ATR or their effectors CHK1 
and CHK2 (Banin et al. 1998; Canman et al. 1998; Hirao et al. 2000; Shieh et al. 2000).  
These phosphorylation events, in addition to key phosphorylation events on mdm2 itself, lead 
to the disruption of the p53/mdm2 interaction and accumulation of p53 protein (Vousden and 
Lu 2002).  A key transcriptional target of the activated p53 is the cyclin dependent kinase 
inhibitor p21.  p21 suppresses the activity of the cyclin dependent kinase CDK2, which then 
prevents entry into S-phase (el-Deiry et al. 1993; Xiong et al. 1993).  This delay in S-phase 
entry allows the cell time to repair the damage and thus prevents duplication of any damage-
induced mutations. 
 The S-phase checkpoint is a critical one as the process of DNA synthesis often 
creates, or reveals, dangerous lesions.  CDC25A is a key target of CHK2 in the S-phase 
checkpoint.  CDC25A is a phosphatase that activates CDK2 by removing a key inhibitory 
phosphate group on Tyrosine 15 (Galaktionov and Beach 1991; Baratte et al. 1992).   Upon 
DNA damage, ATM-activated CHK2 phosphorylates CDC25A, leading to its degradation 
and subsequent inhibition of CDK2 function (Falck et al. 2001).  Two other proteins 
important for the S-phase checkpoint are NBS1 and SMC1.  Both proteins are targeted 
directly by ATM and their loss leads to a defective S-phase checkpoint (Carney et al. 1998; 
Zhao et al. 2000; Yazdi et al. 2002).  It is thought that they directly communicate with the 
replication machinery, although how they contribute to this checkpoint is not well 
understood. 
 The main target of the G2/M checkpoint is the phosphatase CDC25C.  A direct target 
of both CHK1 and CHK2, CDC25C is responsible for removing inhibitory phosphates on 
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Tyrosines 14 and 15 of the cyclin dependent kinase CDC2 (Parker and Piwnica-Worms 
1992), which normally complexes with cyclin B to promote entry into mitosis.  However, 
following DNA damage, CDC25C is phosphorylated by CHK1 or CHK2 and sequestered in 
the cytoplasm, inhibiting its activation of CDC2 (Sanchez et al. 1997; O'Connell et al. 2000).  
This delays entry into mitosis and allows for repair of any accumulated damage. 
 Thus, activation of ATM/ATR and CHK1/CHK2 by DNA damage leads to 
phosphorylation events that target key components of the cell cycle machinery.  In most 
circumstances, this allows time for the cell to repair damage and prevents the cell from 
passing on mutations.  In some instances however, the damage is so extensive that repair is 
not possible.  In these cases, evolution has designed a system in which cells can eliminate 
themselves rather than risk the possibility of multiplying with inherited mutations.  This 
process of DNA damage-induced apoptosis is carried out primarily through the actions of 
p53. 
 
p53 
 As described earlier, activation of ATM/ATR and CHK1/CHK2 by DNA damage 
leads to the stabilization of and activation of the p53 protein.  Induction of p21 and initiation 
of the G1 checkpoint are key consequences of p53 induction, however its role in protecting 
cells from DNA damage and a wide variety of other stresses proves to be far more expansive.  
In addition to DNA damage, oncogene expression also leads to stabilization of p53 through 
induction of the protein ARF, which binds to and inhibits the p53 inhibitor mdm2 (Zhang et 
al. 1998).  Thus, the actions of p53 act as a check on two of the key initiating events of 
tumorigenesis, oncogene activation and mutation-inducing genomic damage. 
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 p53 is probably the most widely studied protein in biology, yet new aspects of its 
biology are still being uncovered.  Primarily a transcription factor, active p53 tetramerizes 
and binds to gene promoters at a 20 bp consensus sequence that is usually present in two 
copies with a 7-9 bp linker sequence (Vogelstein and Kinzler 1992; Pavletich et al. 1993; 
Vogelstein and Kinzler 1994).  The molecular details of transcription initiation by p53 are 
still an area of intense research, but it is thought to act through recruitment of the histone 
acetyl-transferase (HAT) CBP/p300 and the CBP/p300 associated factor P/CAF (Gu et al. 
1997; Scolnick et al. 1997).  These proteins critically modify promoter associated histone 
molecules to enable transcription initiation as well as modifying p53 itself to increase its 
stability.  
 p53 activity requires numerous post-translational modifications.  As mentioned 
before, disruption of the p53/mdm2 interaction following DNA damage involves specific 
modifications on N-terminal serines, specifically, serines 15 and 20.  Additionally 
phosphorylation of threonine 18 and serines 46 and 315 are thought to contribute to 
recruitment of CBP/p300, promoter selectivity, and inhibition of nuclear export.  p53 has also 
been found to be acetylated, sumolated, ubiquitinated and methylated at various C-terminal 
residues, events that seem to be critical for transcriptional activity and stability, and that 
mediate the interactions between p53 and its binding partners (Bode and Dong 2004). 
 Numerous diverse signaling pathways converge on and modify p53 and thus provide 
the context in which p53 executes its life or death decision.  Many of the modifications affect 
the specificity with which p53 binds to certain promoters and others affect its interactions 
with other transcription factors and co-factors.  The net effect, depending on the particular 
context, is cell cycle arrest, mediated by targets such as p21, or apoptosis. 
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 The ability of p53 to induce apoptosis has been shown to depend primarily on its 
ability to induce the transcription of pro-apoptotic target genes.  The first pro-apoptotic target 
gene of p53 to be identified was the Bcl-2 family member Bax, which induces apoptosis by 
inserting into the outer membrane of the mitochondria and allowing the release of 
cytochrome C and subsequent activation of Caspase 9 (Miyashita and Reed 1995).  However, 
the finding that Bax null mice were not deficient in p53-dependent apoptosis prompted the 
search for further targets (Knudson et al. 1995).  Subsequent studies have identified a host of 
p53 target genes that contribute in some way to the apoptotic response.  Apaf1, which 
collaborates with cytochrome C in the activation of Caspase 9 has been shown to be a p53 
target gene, as has the FAS receptor, which is an important activator of the extrinsic 
apoptotic pathway (Owen-Schaub et al. 1995; Soengas et al. 1999).  Additionally, Noxa and 
Puma, which have BH-3 domains in common with the Bcl-2 family of apoptotic factors, have 
been shown to be critical mediators of the p53-dependent apoptotic response (Oda et al. 
2000; Nakano and Vousden 2001).  Recent knockouts of these two proteins, which, like Bax, 
contribute to apoptosis through the release of cytochrome C from the mitochondria, exhibit 
similar phenotypes to the p53 knockout in their response to apoptotic stimuli (Jeffers et al. 
2003; Villunger et al. 2003). 
 In addition to inducing pro-apoptotic target genes, p53 has also been shown to 
promote apoptosis in transcription-independent ways.  Studies have shown that cytoplasmic 
pools of p53 exist that are normally bound to the anti-apoptotic protein Bcl-XL.  Upon 
genotoxic stress, the p53/Bcl-XL interaction is disrupted through competitive interactions 
with p53-induced Puma, at which point freed p53 can bind directly to the mitochondrial 
membrane and contribute to its permeabilization (Chipuk et al. 2004).  The importance of 
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this arm of the p53 pathway is not yet fully known, however it emphasizes the many 
overlapping ways that p53 contributes to the apoptotic response following genotoxic stress. 
Another important target gene of p53 is its inhibitor, the ubiquitin ligase mdm2.  
Induction of mdm2 by p53 provides critical negative feedback regulation, ensuring the 
transience of the p53 response (Barak et al. 1993).  Thus, in the many instances where 
apoptotic death is not warranted, p53 is induced long enough for transient growth inhibition 
but eventually allows for re-entry into the cell cycle. 
  The reputation of p53 as the guardian of the genome has been well earned.  This is 
readily apparent from the number and type of signals that lead to its induction and the 
importance of the downstream pathways that it elicits.  Studies of a wide spectrum of human 
tumors as well as analyses of p53 deficient mice have only reinforced this notion. 
 Studies of human tumors have found that most, if not all, tumors have inactivated p53 
through some mechanism.  In more than half of tumors, p53 is inactivated through a direct 
mutation of the p53 gene.  While some of these mutations are complete or partial deletions, 
the majority are point mutations that result in inactivating amino acid substitutions. This 
leads to accumulation of the mutant protein due to the inability to up-regulate the inhibitor 
mdm2.  It is thought that the accumulation of some of these mutant p53 variants may 
contribute directly to oncogenesis directly either through dominant negative activity or 
through the acquisition of novel function.  p53 can also be inactivated through binding to the 
products of viral oncogenes, through the loss of the ARF gene, or through multiplication or 
over-expression of mdm2.  Certain tumors have also been shown to mislocalize p53 to the 
cytoplasm, inhibiting its function by not allowing it access to target gene promoters 
(Vogelstein et al. 2000).  The message that has been learned from these studies of p53 in 
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human tumors is that in order for cancer to progress, cells must in some way bypass the 
critical barrier that p53 has erected to prevent unregulated growth and proliferation. 
 The critical importance of p53 in cancer development has been also been shown by 
deletion of p53 in mice.  p53 null mice are developmentally normal but develop spontaneous 
tumors, particularly lymphomas and sarcomas, with a very high frequency (Donehower et al. 
1992).  Lymphocytes from these mice are protected against DNA damage induced apoptosis, 
underscoring the importance of p53 in this process (Lowe et al. 1993). 
 While the importance of p53 as a tumor suppressor has been widely established, the 
complex regulation of its function remains an intense area of research.  How various 
signaling pathways such as the NF-κB pathway feed into the regulation of p53 is critically 
important, and by investigating such pathways in the context of p53 we can better understand 
both p53 function and how these pathways contribute to oncogenesis. 
 
IV. Summary 
 The NF-κB and p53 pathways are both critical components of cellular function and 
have important roles in human cancer development.  Understanding how these two families 
interact will give us a more complete understanding of cancer biology and provide useful 
insights into treating this disease.  How non-classical NF-κB factors contribute to this 
relationship, and how they contribute to oncogenesis, has not been appreciated in the past, 
but as more is uncovered about these factors, their importance is becoming clearer.  To that 
end, the work described in this dissertation investigates the role of IκB family member Bcl-3 
in DNA damaged induced p53 function.   The work described contributes to our 
understanding of how Bcl-3 contributes to oncogenesis and provides a novel mechanism of 
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regulating p53 function.  Hopefully, with this knowledge we will add another piece of the 
complex puzzle of understanding human cancer biology. 
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This Chapter was originally published in Genes and Development (2006) 
volume 20, pages 225-235. 
Permission for reprinting has been granted. 
Contributions to this chapter were made by Patricia C. Cogswell. 
 
 
 
 30
  
 
 
Abstract 
 
While Bcl-3 expression in cancer was originally thought to be limited to B-cell 
lymphomas with a 14;19 translocation, more recent evidence indicates that expression of this 
presumptive oncoprotein is significantly more widespread in cancer. However, an oncogenic 
role for Bcl-3 has not been clearly identified. Experiments presented here indicate that Bcl-3 
is inducible by DNA damage and is required for the induction of Hdm2 gene expression and 
the suppression of persistent p53 activity. Furthermore, constitutive expression of Bcl-3 
suppresses DNA damage-induced p53 activation and inhibits p53-induced apoptosis through 
a mechanism that is at least partly dependent on the upregulation of Hdm2. The results 
provide insight into a mechanism whereby altered expression of Bcl-3 leads to tumorigenic 
potential. Since Bcl-3 is required for germinal center formation, these results indicate 
functional similarities with the unrelated Bcl-6 oncoprotein in suppressing potential p53-
dependent cell-cycle arrest and apoptosis in response to somatic hypermutation and class 
switch recombination.  
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Introduction 
 
Bcl-3 was first identified through cloning of the t(14;19) breakpoint junction which 
occurs in a subset of B cell chronic lymphocytic leukemias (B-CLL) (McKeithan et al. 1987).  
A member of the ankyrin-repeat containing IκB family of NF-κB inhibitors (Hayden and 
Ghosh 2004), Bcl-3 is apparently unique in that, unlike other IκBs, its localization is nuclear 
and it contains a transactivation domain.  Studies have shown that Bcl-3 preferentially binds 
to NF-κB p50 and p52 homodimers (Bours et al. 1993; Nolan et al. 1993), and through its 
interaction with coactivators such as CBP/p300, SRC-1, and Tip60 (Na et al. 1998; Dechend 
et al. 1999) and co-repressors such as HDAC1 (Wessells et al. 2004), can both activate and 
repress transcription of target genes.   Importantly, genetic knockout of Bcl-3 leads to 
impaired microarchitecture in spleen and lymph nodes with associated germinal center 
defects (Franzoso et al. 1997; Schwarz et al. 1997).  
Relatively high levels of Bcl-3 expression in certain B-CLL suggests that it may play 
a direct role in oncogenesis. In this regard, expression of Bcl-3 is sufficient to transform 
NIH3T3 cells (Viatour et al. 2004). Importantly, Bcl-3 has now been shown to be more 
widely expressed in cancer with expression in a significant number of breast cancers 
(Cogswell et al. 2000), nasopharyngeal carcinoma (Thornburg et al. 2003), lymphomas 
(Canoz et al. 2004), and hepatocellular carcinoma and pancreatic cancer (B. O’Neil, 
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unpublished).  The findings that Bcl-3, in complex with p52, can promote transcription of the 
genes encoding the cell cycle regulator cyclin D1 and the anti-apoptotic Bcl-2 protein 
suggest one potential oncogenic mechanism (Westerheide et al. 2001; Viatour et al. 2003), 
but a more complete understanding of the role of Bcl-3 in human cancers is still lacking. 
p53 is a crucial guardian of genomic integrity and its importance as a tumor 
suppressor is underscored by the fact that it is either mutated or otherwise dysregulated in the 
majority of human cancers (Vousden and Lu 2002; Vousden and Prives 2005).  Normally, 
p53 remains at low levels through its interaction with the E3 ubiquitin ligase, Hdm2.   Upon 
cellular stress or oncogene activation, this interaction is disrupted and p53 rapidly 
accumulates in the nucleus where it can activate a number of target genes, including the 
cyclin dependent kinase inhibitor p21 (el-Deiry et al. 1993), pro-apoptotic genes Noxa and 
Puma (Oda et al. 2000; Nakano and Vousden 2001; Yu et al. 2001), and its own inhibitor 
Hdm2 (Barak et al. 1993). Recent evidence also suggests that p53 can play a direct apoptotic 
role in the mitochondria, independent of its trancriptional function (Chipuk et al. 2004).  
Ultimately, depending on the type and intensity of the signal, as well as the cellular context, 
p53 stabilization results in either cell cycle arrest or apoptosis.  Loss of p53 function, through 
either mutation or an alternative mechanism such as over-expression of Hdm2, leads to 
dysregulated growth, protection against apoptosis, and genomic instability, allowing for the 
accumulation of secondary mutations (Bond et al. 2005; Vousden and Prives 2005). 
Based on the ability of NF-κB to regulate cell death pathways (Ghosh and Karin 
2002; Kucharczak et al. 2003) and on recent studies that suggest a potential link between 
Bcl-3 and the DNA damage response (Boulton et al. 2002; Watanabe et al. 2003), we have 
investigated a potential role for Bcl-3 in regulating the apoptosis response to DNA damage.  
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We find that Bcl-3 is transiently upregulated by DNA damage and that constitutive 
expression of Bcl-3 in MCF-7 cells leads to a strong suppression of DNA damage-induced 
cell death without a significant effect on NF-κB-regulated anti-apoptotic genes. Importantly, 
Bcl-3 expression leads to suppression of p53 induction following DNA damage, resulting in 
the inhibition of expression of the p53 target genes Noxa and Puma. Analysis of Bcl-3 null 
MEFs or cancer cells knocked down for Bcl-3 reveals that loss of Bcl-3 leads to an enhanced 
p53 response.  One mechanism by which this inhibition occurs is through Bcl-3 mediated 
induction of the p53 inhibitor Hdm2.  Both stable and transient over-expression of Bcl-3 
leads to increased Hdm2 expression, and siRNA-mediated knockdown of Bcl-3 blocks 
expression of Hdm2.  Analysis of Bcl-3 null fibroblasts reveals that Bcl-3 is required for the 
induction of Mdm2 gene expression and for limiting the p53 activation response.  Disruption 
of the p53-Hdm2 interaction in Bcl-3 expressing cells functions to rescue the p53 inhibition 
and apoptotic response.  Furthermore, the data support a model whereby Bcl-3, like the 
unrelated oncoprotein Bcl-6, functions to suppress p53-dependent cell-cycle arrest and 
apoptosis in germinal center B-cells undergoing somatic mutation and class switch 
recombination.  Our results provide significant new insight into oncogenic mechanisms 
associated with Bcl-3 and provide evidence that Bcl-3 is required for p53 to induce 
expression of Hdm2 gene expression. 
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Results 
 
Elevated Bcl-3 expression inhibits DNA-damage induced apoptosis. 
In addition to its relatively high expression in B-CLL carrying the t(14;19) 
translocation, Bcl-3 has also been found to be elevated in a number of other human cancers 
including nasopharyngeal carcinoma (Thornburg et al. 2003), breast cancer (Cogswell et al. 
2000), lymphomas (Canoz et al. 2004), and hepatocellular carcinoma (O’Neil et al., 
unpublished).  In order to understand the consequences of Bcl-3 constitutive expression and 
to investigate its potential role in driving oncogenesis, we engineered the MCF-7 breast 
cancer cell line to express relatively high levels of Bcl-3 (MCF-7B).  Expression of Bcl-3 in 
the MCF-7B cells is comparable to its expression in several cancer cell lines, including 
Karpas 299 cells, which have been previously reported to express high levels of Bcl-3 
(Nishikori et al. 2003) and in the fibrosarcoma line, HT-1080 (Figure 1.1A). 
One characteristic shared by many human cancers is the inability to appropriately 
respond to genomic insults.  To determine if Bcl-3 over-expression might contribute to this 
deficiency, we treated MCF-7 and MCF-7B cells with either UV-C or the DNA damage-
inducing drug cisplatin and measured the apoptotic response.  Intriguingly, MCF-7B cells 
exhibit a significant resistance to DNA damage-induced cell death (Figure 1.1B).  As 
expected, the DNA damage-induced cell death in the parental MCF-7 line is dependent on 
p53 activity, as co-treatment with the p53 inhibitor Pifithrin-α (Komarov et al. 1999) inhibits 
the apoptotic response following UV treatment (Figure 1.1C).   
Somewhat surprisingly, no increase was observed in the MCF-7B cells of expression 
of known anti-apoptotic genes that are reportedly regulated by NF-κB following treatment 
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with UV or cisplatin (D. Kashatus, Unpublished).  As such we sought to investigate other 
potential mechanisms for this anti-apoptotic activity. 
 
Bcl-3 inhibits the p53 response to DNA damage. 
As p53 is a critical mediator of the apoptotic response following DNA damage 
(Vousden and Prives 2005), and given that DNA damage-induced apoptosis in MCF-7 cells 
is p53 dependent (Figure 1.1C), we sought to investigate whether expression or activation of 
this tumor suppressor is affected by constitutive expression of Bcl-3.  Interestingly, Bcl-3 
protein levels increase transiently between 2 and 6 hours following UV treatment in the 
parental MCF-7 cells, returning to basal levels by 24 hrs, suggesting that this oncoprotein 
may have a role in the UV response.  The increase in Bcl-3 protein is likely to be at the level 
of protein stability as we detect no increase in Bcl-3 mRNA following UV treatment (D. 
Kashatus, Unpublished).  The transient nature of the response is consistent with the report 
that p53 can negatively regulate Bcl-3 protein (Rocha et al. 2003), as the loss of Bcl-3 
coincides with the accumulation of p53. 
As expected, p53 is induced in the parental MCF-7 cells in response to UV treatment, 
with peak levels reached approximately 8 hours following treatment. Intriguingly, the p53 
response in MCF-7B cells is significantly muted, with peak p53 protein levels being 
considerably lower than in the parental cells (Figure 1.2A).  This down-regulation of the p53 
response is not correlated with reduced p53 mRNA levels (Figure 1.2B). To ensure that the 
resulting suppression of the p53 response by Bcl-3 is not a consequence of creating and 
selecting stable cells, we transiently expressed flag-tagged Bcl-3 in parental MCF-7 cells and 
treated the cells with UV.  Consistent with the results from the stable lines, increased 
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expression of Bcl-3 leads to a decrease in the levels of p53 protein 4 hrs following UV 
treatment (Figure 1.2C).  Further, we transfected expression vectors for p53 plus Bcl-3 or 
p53 plus empty vector along with the pg13 p53 responsive reporter (el-Deiry et al. 1993) into 
parental MCF-7 cells to test p53 transcriptional activity in the presence of excess Bcl-3. As 
expected, p53 activated the luciferase reporter while co-expression of Bcl-3 partially 
suppressed this response (Figure 1.2D).  Basal p53 activity is very low in these cells, thus 
any decrease in basal p53 activity upon Bcl-3 over-expression falls below the detection limit 
of the assay. Taken together, these results indicate that expression of Bcl-3 can suppress the 
activation of p53 (see Discussion). 
To determine the effect of Bcl-3 expression on the induction of p53 target genes, real-
time quantitative PCR was performed on cDNA generated from MCF-7 and MCF-7B cells 
exposed to UV.  The cyclin dependent kinase inhibitor p21 is an important target of p53 that 
functions in p53 dependent cell cycle arrest.  Real time PCR analysis of p21 mRNA indicates 
that Bcl-3 expression leads to an almost complete loss of p21 induction by UV (Figure 1.2E).  
Other important gene targets of p53 encode pro-apoptotic proteins, including Noxa and 
Puma, members of the BH3-only class of Bcl-2 homologues.  Recent knockouts of these p53 
targets indicate that they are essential effectors of p53 dependent apoptosis (Jeffers et al. 
2003; Villunger et al. 2003).  Analysis of these gene products indicates that, as with p21, 
constitutive Bcl-3 expression leads to a loss of their induction following UV treatment 
(Figure 1.2E).  Notably, while p21 and Noxa expression are almost completely abrogated, the 
levels of Puma are only modestly inhibited, consistent with reports of p53-dependent and 
independent induction of this gene (Jeffers et al. 2003).  
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Knockdown or knockout of Bcl-3 expression leads to enhanced p53 activation following DNA 
damage. 
To further analyze the role of Bcl-3 in DNA damage-induced p53 function we 
analyzed the outcome of knockdown of Bcl-3 in HT1080 fibrosarcoma cells since these cells 
express a functional form of p53 (Suzuki et al. 2003) as well as elevated Bcl-3.  siRNA 
against Bcl-3, but not the control siRNA, leads to a near complete loss of the faster migrating 
form of Bcl-3 and to a significant reduction in the slower migrating form. Importantly, 
knockdown of expression of Bcl-3 generates enhanced basal and UV-induced p53 expression 
(Figure 1.3A). These results indicate that elevated expression of Bcl-3, at least in certain p53 
wild-type cancer cells, represses the activation potential of p53. In order to extend these 
studies and to analyze the outcome of loss of Bcl-3 through a mechanism independent of 
siRNA knockdown, we analyzed the p53 response in Bcl-3 +/+ and Bcl-3-/- primary mouse 
embryonic fibroblasts. Exposure of these cells to UV leads to the expected p53 response in 
wild-type cells, but to elevated levels of p53 at the 24 hr time point in Bcl-3 null cells (Figure 
1.3B). Consistent with the observed p53 response in Bcl-3 null fibroblasts, treatment of these 
cells with UV leads to an increase in apoptosis compared to the wild-type cells (Figure 1.3C).  
Importantly, co-treatment with pifithrin-α leads to a reduction in the apoptotic response to 
UV in the Bcl-3 -/- cells, indicating that this response is at least partly dependent on p53 
activity (Figure 1.3C).  Additionally, loss of Bcl-3 does not sensitize MEFs to TNFα-induced 
apoptosis (Supplemental Figure 1.1) consistent with the idea that the protection it provides is 
specific for p53-dependent inducers of apoptosis.  These results are consistent with a role for 
Bcl-3 in suppressing the p53 activation response, both when Bcl-3 is constitutively expressed 
at high levels and when Bcl-3 is transiently induced in response to DNA damage.  
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Bcl-3 expression leads to an increase in Hdm2 levels. 
p53 activation is controlled through modifications (such as phosphorylation) and 
through interactions with its inhibitor Hdm2 (Vousden and Prives 2005). Analysis of UV-
induced phosphorylation of p53 (ser15 and ser20) in MCF-7B cells indicated that this 
modification tracked with proteins levels (D. Kashatus, Unpublished), suggesting that Bcl-3 
expression does not block p53 ser15 or ser20 phosphorylation.  To analyze how high levels 
of expression of Bcl-3 might lead to the loss of p53 induction by DNA damage, we 
investigated the levels of the p53 inhibitor Hdm2.  Western analysis of MCF-7 and MCF-7B 
cells reveals that MCF-7B cells exhibit consistently higher Hdm2 levels (Figure 1.4A, 1st 
Panel), providing a potential mechanism for the inhibition of p53 seen in these cells.  
Importantly, transient over-expression of Bcl-3 in parental MCF-7 cells also leads to 
increased Hdm2 protein (Figure 1.4A, 2nd panel), confirming that the increase seen in the 
stable cells is not an artifact of clonal selection.  This increase in Hdm2 in MCF-7B cells is 
also evident at the RNA level, as real-time quantitative PCR indicates a roughly 3-fold 
increase in Hdm2 levels in MCF-7B cells relative to parental MCF-7 cells (Figure 1.4B).  To 
show that this effect is not unique to MCF-7 cells, we transiently transfected Bcl-3 into the 
U-2OS osteosarcoma line.  Consistent with the results from MCF-7 cells, increasing levels of 
Bcl-3 leads to proportionately increased levels of Hdm2 protein in these cells (Figure 1.4C). 
To determine whether the Bcl-3 dependent increase in Hdm2 might be due to a direct 
role for Bcl-3 at the Hdm2 promoter, we performed ChIP analyis using PCR primers specific 
for the P2 promoter region of the Hdm2 promoter, flanking the two conserved p53 binding 
sites.  As reported for other p53 inducible genes (Espinosa et al. 2003), there are relatively 
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low levels of p53 at the promoter under basal conditions, with a several fold increase 
following UV treatment (Figure 1.4D).  Notably, the levels of p53 at the promoter 4 hrs post 
UV are lower in the MCF-7B cells when compared to the parental MCF-7 cells, consistent 
with the lower levels of stabilized p53 in these cells.  Intriguingly, Bcl-3 is also present at the 
Hdm2 promoter at levels consistent with its expression in the cells.  In MCF-7 cells, Bcl-3 is 
not detectable basally but increases as the protein levels increase, while in the MCF-7B cells 
it is present both basally and after UV treatment (Figure 1.4D).  As a control, it is shown that 
neither Bcl-3 nor p53 are present at significant levels at the β-actin promoter. 
The observed recruitment of Bcl-3 to the Hdm2 promoter led us to investigate 
potential binding sites for Bcl-3 in the Hdm2 P2 promoter region.  We identified a putative 
NF-κB binding site 275 bp upstream of the exon 2 start site that is conserved in the mouse 
Mdm2 promoter (Supplemental Figure 1.2A).  Intriguingly, gel shift analysis using a 32P-
labeled oligonucleotide probe specific for this site shows increased binding to the probe in 
the MCF-7B cells compared to the parental MCF-7 cells.  Further analysis using antibodies 
specific for various NF-κB subunits shows that the complex binding this site contains both 
p50 and p52, known binding partners of Bcl-3 (Supplemental Figure 1.2B). 
Additionally, we performed reporter assays using Hdm2 P2 luciferase reporters 
containing various portions of the P2 promoter.  The two reporters containing the region of 
the promoter that includes the NF-κB binding site (Hdm2-Luc-01 & Hdm2-Luc-02) 
consistently exhibit increased activity in the MCF-7B cells compared to the parental MCF-7 
cells.  Conversely, the reporter construct that lacks the region containing the NF-κB site 
(Hdm2-Luc-03) exhibits no difference between the two cell types (Supplemental Figure 
1.2C).  While we can’t rule out the existence of other important regulatory sites in this 
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deleted region, these data are consistent with the importance of this binding site for Bcl-3-
induced Hdm2 transcription. 
 
Bcl-3 is required for Hdm2 gene expression. 
Given that Bcl-3 is recruited to the Hdm2 promoter following UV treatment (Figure 
1.4D), and that its elevated expression leads to increased levels of Hdm2, we sought to 
determine whether Bcl-3 is required for Hdm2 expression.  Knockdown of Bcl-3 by RNAi in 
both MCF-7 and Karpas 299 cells leads to a near complete loss of Hdm2 expression, 
consistent with Bcl-3 being required for basal Hdm2 expression in these cells (Figure 1.5A).  
Note that Karpas 299 cells are reported to express mutant p53 (Hubinger et al. 2001), 
suggesting a lack of involvement of p53 in control of Hdm2 gene expression in these cells. 
To further test our hypothesis, primary fibroblasts from mice lacking Bcl-3 and their wild-
type littermates were analyzed following DNA damage.  When wild type or Bcl-3 null MEFs 
are treated with either UV or the DNA damage inducing drug cisplatin, cells lacking Bcl-3 
fail to induce mdm2 mRNA to the levels seen in wild-type cells (Figure 1.5B). Consistent 
with this, the induction of Mdm2 protein levels is severely repressed in Bcl-3 -/- cells as 
compared to their wild-type counterparts (Figure 1.5C).  In order to determine if suppression 
of Bcl-3 inhibits the induction of Hdm2 in another cell type, siRNA was utilized to suppress 
Bcl-3 expression in HT-1080 cells, which express functional p53 (Suzuki et al. 2003). 
Knockdown of Bcl-3 in HT-1080 cells also leads to a suppression of the induction of Hdm2 
following UV treatment (Figure 1.5D).  These results demonstrate an important role for Bcl-
3 in controlling Hdm2/mdm2 gene expression in several cell types. 
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Disruption of the p53-Hdm2 interaction in MCF-7B cells rescues the DNA damage-induced 
p53 response. 
In order to determine if Bcl-3-mediated repression of DNA damage-induced p53 stability 
involves Hdm2, we analyzed whether disruption of the p53-Hdm2 interaction is able to 
rescue p53 responsiveness in MCF-7B cells. The recently described compound RITA 
(reactivation of p53 and induction of tumor cell apoptosis) has been shown to bind to p53 
both in vitro and in vivo and to prevent its interaction with Hdm2 (Issaeva et al. 2004).  
MCF-7 and MCF-7B (Bcl-3 expressing) cells were exposed to RITA or to diluent, and to UV 
treatment.  The results demonstrate the expected p53 induction in MCF-7 cells and the strong 
suppression of p53 activation in MCF-7B cells.  Importantly, exposure of the MCF-7B cells 
to RITA leads to a rescue of the Bcl-3-controlled repression of p53 as evidenced by higher 
levels of p53 stabilization than in cells treated with UV and vehicle control (Figure 1.6A).  
To test the Hdm2 dependence in another way, we transfected MCF-7B cells with either a 
control siRNA or an siRNA specific for Hdm2.  Consistent with what we see following 
RITA treatment, knockdown of Hdm2 in MCF-7B cells leads to a rescue of the p53 response 
following UV treatment (Figure 1.6B).  Collectively, these data indicate that the repression of 
p53 induction seen in MCF-7B cells is dependent on the p53-Hdm2 interaction, consistent 
with the model that increased Hdm2 levels in MCF-7B cells are responsible for the 
repression. 
To determine if the protection against apoptosis observed in MCF-7B cells (see 
Figure 1.1) is dependent on Hdm2-mediated repression of p53, MCF-7 and MCF-7B cells 
were either treated with UV alone or with UV plus RITA and the apoptotic response was 
measured.  Consistent with the data from figure 1.1, MCF-7B cells are significantly protected 
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against apoptosis when treated with UV alone.  However, cotreatment with RITA rescues the 
apoptotic defect in MCF-7B cells.  Importantly, cotreatment with UV and RITA results in 
equivalent levels of apoptosis in MCF-7 and MCF-7B cells, demonstrating that the 
interaction between p53 and Hdm2 is critical for the observed apoptotic differences in the 
two cell lines (Figure 1.6C).  Similarly, siRNA-mediated knockdown of Hdm2 is able to 
restore the UV-induced apoptotic response in MCF-7B cells (Supplemental Figure 1.3), 
albeit to a lesser extent than treatment with RITA. This is likely due to a less than 100% 
transfection efficiency in these cells leading to an incomplete knockdown of Hdm2. These 
data further demonstrate the importance of the p53-Hdm2 interaction the antiapoptotic 
effects of Bcl-3.  Collectively, these data indicate that the Bcl-3-mediated protection against 
DNA damage-induced apoptosis involves the regulated interaction between p53 and Hdm2 
and support the hypothesis that Bcl-3-controlled induction of Hdm2 is responsible for the 
observed repression of p53. 
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Discussion 
 
The data presented here reveal a surprising pro-oncogenic role for the oncoprotein 
Bcl-3, namely its ability to suppress the activation of the p53 tumor suppressor protein in 
response to DNA damage. A major proposed mechanism in this regulatory circuit is the 
ability of Bcl-3 to induce the expression of Hdm2, the inhibitor of p53.  The experiments 
demonstrate that expression of Bcl-3 leads to an increase in Hdm2 levels and to a subsequent 
loss of DNA damage induced p53 protein stability.  The consequence of the Bcl-3 mediated 
inhibition of p53 is a loss of induction of p53 target genes and protection against DNA 
damage-induced apoptosis.  Interestingly, the loss of Bcl-3 leads to the inability of p53 to 
induce hdm2 transcription and, correspondingly, to enhanced p53 protein stability, 
suggesting that a normal physiological role of Bcl-3 is to limit the p53 activation response.  
Bcl-3 over-expression is characteristic of a growing number of human cancers 
(Cogswell et al. 2000; Thornburg et al. 2003; Canoz et al. 2004), yet a specific oncogenic 
role for Bcl-3 in these cancers has been elusive.  Recently we and others (Westerheide et al. 
2001; Rocha et al. 2003) demonstrated that Bcl-3 can contribute to cyclin D1 transcription, a 
key component in driving cell cycle progression. The finding that Bcl-3 can inhibit p53 
function provides a novel mechanism for how aberrant Bcl-3 expression can fulfill an 
oncogenic function.  The importance of p53 as a tumor suppressor is illustrated by the fact 
that it is mutated or lost in over half of all human cancers tested (Vousden and Lu 2002; 
Vousden and Prives 2005) and presumably cancer cells with wild-type p53 have 
compromised its function through different mechanisms.  Loss of the tumor suppressor ARF 
and high level expression of Hdm2 have been thought to be two of main ways that this is 
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achieved.  Consistent with this, it has been reported (Bond et al. 2004) that an Hdm2 
promoter polymorphism increases affinity for the transcription factor Sp1 promoting high 
level transcription and subsequent attenuation of the p53 response. Additionally, N-Myc 
(Slack et al. 2005) and estrogen receptor-α (Phelps et al. 2003) can regulate Hdm2 in a p53-
independent fashion.  Similarly, Bcl-3, through induction of Hdm2, would provide a level of 
inhibition to p53 that tumor cells need to progress, bypassing the need for mutation or 
deletion of p53.   
Current models of p53 activation by DNA damage suggest that post-translational 
modification of p53 disrupts its interaction with Hdm2 and thus it might be suggested that 
any increase in Hdm2 protein levels would have a minimal effect on p53 protein stability 
following DNA damage.  However, it is likely that the dynamics of the DNA damage 
response are more complex.  First, it has been reported that modification of both p53 and 
Hdm2 are important for the disruption of the interaction (Mayo et al. 1997a; Hay and Meek 
2000), suggesting that a consistent supply of newly transcribed Hdm2 provided by Bcl-3 
would provide a steady stream of unmodified Hdm2 to re-engage p53.  Further, the fact that 
p53-induced Hdm2 provides negative feedback regulation of p53 suggests that at some point 
following the initial damage event, the newly transcribed Hdm2 is able to rebind to p53 and 
turn off the response.  Consistent with this, our data indicate that Bcl-3-induced Hdm2 will 
indeed have the effect of dampening the p53 response.  This conclusion is further supported 
by the many reports of Hdm2 over-expression in human cancers (Momand et al. 1998). 
Furthermore, while our data indicate that Bcl-3 can regulate p53 through induction of 
Hdm2, we cannot rule out additional roles for Bcl-3 in regulating p53 function.  For example, 
certain p53-dependent genes have NF-κB consensus sites in their promoters and Bcl-3, 
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presumably through interactions with the p50 or p52 NF-κB subunits, may play a direct role 
in the regulation of those genes.  In fact, we have found recruitment of Bcl-3 as well as other 
NF-κB subunits to a number of those promoters and are currently investigating those 
mechanisms (D. Kashatus, Unpublished).  Additionally, higher levels of Bcl-3 may affect 
NF-κB dimer composition and indirectly affect NF-κB regulation of those promoters.  It is 
also possible that Bcl-3 regulates p53 protein levels or functional activity through additional 
mechanisms.  While we find no evidence that Bcl-3 has a role in direct transcriptional 
regulation of p53, it may affect p53 through control of stability or translational efficacy.  
The finding of this novel function for Bcl-3 raises intriguing questions regarding a 
role for Bcl-3 in development, immune and inflammatory function, and in the stress 
response. An indication of what that role may be comes from a the recent finding that Bcl-6, 
a transcriptional repressor also found aberrantly expressed in B-cell lymphomas which is 
unrelated to Bcl-3, directly inhibits p53 transcription in germinal center B-cells (Phan and 
Dalla-Favera 2004).  This negative regulation of p53 is presumed to be important to allow 
these cells to tolerate the DNA damage required for immunoglobulin class switch 
recombination and somatic hypermutation without mounting an apoptotic response.  Our new 
data, plus the fact that Bcl-3 knockout mice, like the Bcl-6 knockouts, fail to develop 
germinal centers (Franzoso et al. 1997), suggests that Bcl-3 may function to block p53 
activation in germinal center B-cells, but through a different mechanism than that reported 
for Bcl-6. It has also been shown that expression of Bcl-3 correlates with survival in 
adjuvant-induced T-cells (Mitchell et al. 2001).  Activated T-cells require a survival signal 
following antigen stimulation in order to avoid apoptosis and to undergo clonal expansion.  
The apoptotic signal has been shown to be mediated by the p53 family member p73 (Wan 
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and DeGregori 2003).  Given its role in p53 inhibition, Bcl-3 may protect activated T-cells 
through down-regulation of this apoptotic response by inhibiting p73 through a similar 
mechanism.  The failure of Bcl-3 null mice to mount an effective T-cell response to influenza 
virus supports this role for Bcl-3 (Franzoso et al. 1997). Finally, we observe that Bcl-3 is 
activated by UV, potentially at the level of protein stabilization (see Fig. 1.2). Given that loss 
of Bcl-3 leads to enhanced p53 activation and to enhanced apoptosis (Fig. 1.3), it is likely 
that the induction of Bcl-3 by UV (or by other DNA damaging agents) functions normally to 
limit p53 induction and apoptosis.  
Given the previous intriguing results regarding both cooperative (Ryan et al. 2000) 
and antagonistic (Webster and Perkins 1999) relationships between the NF-κB and p53 
pathways, it would be expected that the findings reported here relate to these original 
findings. However, the direct relationship between Bcl-3 expression and the classic NF-κB 
pathway remains unclear. In this regard, it has been reported that Bcl-3 gene expression can 
be induced in an NF-κB-dependent manner (Brasier et al. 2001). Our analyses of p65 null 
MEFs, however, do not reveal a similar defect in mdm2 expression or p53 stabilization (D. 
Kashatus, Unpublished), suggesting the Bcl-3 mediated regulation is p65 independent.  
Further analysis of cells lacking other NF-κB subunits, specifically p50 and p52, should 
allow us to determine their requirement in this regulation.  The fact that loss of IKKβ leads to 
a loss of mdm2 induction suggests that this kinase may function upstream of Bcl-3 in this 
response (Tergaonkar et al. 2002).  IKKβ may act through regulation of p50 or p52, or it 
could potentially be involved in the DNA damage-induced stabilization of Bcl-3 through 
direct phosphorylation. 
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In summary, our findings provide a critical understanding of the functional 
consequences of Bcl-3 expression in human cancer cells and could potentially have direct 
clinical applications for cancer treatment.  Unlike Bcl-3, p53 and Hdm2 are popular targets 
for drug development and these findings may provide rationale for a potential new 
intervention pathway for certain cancers.  These data also provide an additional link in the 
expanding relationships between the NF-κB/IκB family and p53 and open new avenues for 
exploration into how these two important protein families interact to control oncogenesis. 
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Figure 1.1  
 
Over-expression of Bcl-3 inhibits DNA damage induced apoptosis  (A) Expression of 
Bcl-3 in MCF-7, MCF-7B, Karpas 299 and HT-1080 cells.  Western blots of extracts from 
indicated cell lines were probed with antibodies against Bcl-3 and β-tubulin.  (B) MCF-7B 
cells are protected against DNA damage-induced apoptosis.  MCF-7 and MCF-7B cells were 
left untreated, or treated with 40 J/m2 UV-C or 10 µg/ml cisplatin as indicated.  18 hrs 
following treatment apoptosis was measured by flow cytometric analysis of Annexin-V 
staining.  (C) UV-induced apoptosis in MCF-7 cells is p53 dependent.  MCF-7 cells were 
treated with DMSO, 10 µM pifithrin-α, 40 J/m2 UV-C plus DMSO or 40 J/m2 UV-C plus 10 
µM pifithrin-α as indicated.  18 hrs following treatment apoptosis was measured by flow 
cytometric analysis of Annexin-V staining. 
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Figure 1.2 
 
Bcl-3 over-expression inhibits DNA damage-induced p53 activity.  (A) UV-induced p53 
protein levels are reduced in MCF-7B cells.  MCF-7 and MCF-7B cells were treated with 40 
J/m2 UV-C for the indicated times and western analysis was performed on whole cell extracts 
using antibodies against Bcl-3, p53 and β-tubulin.  (B) Over-expression of Bcl-3 does not 
affect p53 mRNA levels.  MCF-7 and MCF-7B cells were treated with 40 J/m2 UV-C for the 
indicated times and relative expression of p53 was measured by quantitative real-time PCR.  
Expression levels were normalized to expression of glucuronidase-β and the values represent 
the fold increase or decrease relative to untreated MCF-7 cells (lane 1).  (C) Transient 
expression of Bcl-3 leads to decreased p53 protein levels following UV treatment.  MCF-7 
cells were transfected with either empty vector or 2 µg or 4 µg of pCMV-flag-Bcl-3.  Two 
days following transfection, the cells were left untreated or treated with 50 J/m2 UV-C for 4 
hrs and western analysis was performed with antibodies against the flag epitope, p53 or β-
tubulin.  (D) Transient expression of Bcl-3 inhibits p53 transcriptional activity.  MCF-7 cells 
were transfected with 50 ng of pg-13-luciferase and 5 ng renilla luciferase plus 100 ng of 
pCMV-flag-Bcl-3 and pCMV-flag-p53 where indicated.  Firefly luciferase activity was 
measured and normalized to renilla luciferase.  Values represent fold increase over basal 
activity (lane 1).    (E) DNA damage-induced expression of p53 target genes is lost in MCF-
7B cells.  MCF-7 and MCF-7B cells were treated with 40 J/m2 UV-C for the indicated times 
and relative expression of p21, Noxa and Puma was measured by quantitative real-time PCR.  
Expression levels were normalized to expression of glucuronidase-β and the values represent 
the fold increase or decrease relative to untreated MCF-7 cells (lane 1). 
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Figure 1.3 
 
Loss of Bcl-3 leads to increased levels of p53 following DNA damage and sensitivity to 
DNA damage-induced apoptosis.  (A) Knockdown of Bcl-3 results in an increase of UV-
induced p53 protein.  HT-1080 cells were transfected with a control siRNA or an siRNA 
targeting Bcl-3.  48 hrs following the transfection, cells were treated with 40 J/m2 UV-C for 
the indicated timepoints.  Western analysis was performed on whole cell extracts using 
antibodies against Bcl-3, p53 and β-tubulin.  (B) Bcl-3 null MEFs have increased p53 levels 
following UV treatment.  Wild-type and Bcl-3 deficient mouse embryonic fibroblasts were 
treated with 40 J/m2 UV-C for the indicated timepoints. Western analysis was performed on 
whole cell extracts using antibodies against p53 and β-tubulin.  (C) Bcl-3 null MEFs are 
sensitized to p53 dependent UV-induced apoptosis.  Bcl-3+/+ and Bcl-3-/- MEFs were 
treated with DMSO, 10 µM pifithrin-α, 40 J/m2 UV-C plus DMSO or 40 J/m2 UV-C plus 10 
µM pifithrin-α as indicated. 18 hrs following treatment, apoptosis was measured by flow 
cytometric analysis of Annexin-V staining. 
 53
 
 54
Figure 1.4 
 
Over-expression of Bcl-3 leads to an increase in Hdm-2 expression.  (A) Both transient 
and stable over-expression of Bcl-3 lead to higher basal levels of Hdm-2 protein. Whole cell 
extracts were prepared from MCF-7 and MCF-7B cells as well as MCF-7 cells transfected 
with 8 µg of either empty vector or pCMV-flag-Bcl-3 and western analysis was performed 
using antibodies against Bcl-3, Hdm-2 and β-tubulin.  (B) MCF-7B cells have higher basal 
levels of Hdm-2 RNA. Real-time quantitative PCR was performed on cDNA prepared from 
MCF-7 and MCF-7B cells using primers specific for Bcl-3 and Hdm-2.  Expression levels 
were normalized to expression of glucuronidase-β and values represent fold difference 
relative to MCF-7 (lane 1) for each gene tested.  (C) Transient over-expression of Bcl-3 leads 
to an increase in Hdm-2 levels in U-2OS cells.  U-2OS cells were transfected with 0-200 ng 
of pCMV-flag-Bcl-3 in 50 ng increments.  Total DNA content was brought to 200 ng with 
pCMV-flag vector.  48 hrs following transfection, western analysis was performed on whole 
cell extracts using antibodies against Bcl-3, Hdm-2 and β-tubulin.  (D) Bcl-3 is present at the 
Hdm-2 promoter at higher levels in MCF-7B cells.  MCF-7 and MCF-7B cells were treated 
with 40 J/m2 UV-C for either 0 or 4 hours and Chromatin immunoprecipitation was 
performed using antibodies specific for p53, Bcl-3 or no antibody.  Real-time quantitative 
PCR was performed on precipitated DNA using primers specific for the p2 promoter region 
of the Hdm-2 gene and for the promoter region of the β-Actin gene.  Values are normalized 
against the input DNA and are represented as percent of input for each given sample.  Each 
value represents the mean of three independent measurements of the precipitated DNA and 
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the error bars represent one standard deviation.  The experiment was repeated three times 
with identical results. 
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Figure 1.5 
 
Loss of Bcl-3 leads to a decrease in basal and DNA damage-inducible Hdm2 expression.  
(A) Knockdown of Bcl-3 in human cancer cells leads to loss of Hdm-2 expression.  MCF-7 
and KARPAS 299 cells were transfected with either control siRNAs or siRNAs specific for 
Bcl-3.  48 hours following transfection, western analysis was performed on whole cell 
extracts using antibodies specific for Bcl-3, Hdm-2 and β-tubulin.  (B) DNA damage fails to 
induce Mdm-2 RNA in Bcl-3 deficient fibroblasts.  Wild type and Bcl-3-null MEFs were 
treated with either 40 J/m2 UV-C or 10 µg/ml cisplatin for the indicated times and Mdm-2 
gene expression was measured by quantitative real-time PCR.  Expression levels were 
normalized to expression of GAPDH and the values represent the fold increase or decrease 
relative to untreated wild-type MEFs (lane 1).  (C) DNA damage fails to induce Mdm-2 
protein in Bcl-3 deficient fibroblasts.  Wild type and Bcl-3-null MEFs were treated with 40 
J/m2 UV-C for the indicated times and western blots were performed on whole cell extracts 
using antibodies specific for Mdm-2 and β-tubulin.  (D) Knockdown of Bcl-3 impairs the 
ability of DNA damage to induce Hdm-2 in HT-1080 cells.  HT-1080 cells were transfected 
with either control siRNAs or siRNAs specific for Bcl-3.  48 hours following transfection, 
cells were treated with 40 J/m2 UV-C for the indicated times and western analysis was 
performed on whole cell extracts using antibodies specific for Bcl-3, Hdm-2 and β-tubulin. 
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Figure 1.6 
 
Disruption of the p53-Hdm2 interaction rescues the effects of Bcl-3 over-expression. (A) 
Disruption of the p53-Hdm-2 interaction restores the ability of UV to induce p53 in MCF-7B 
cells.  MCF-7 and MCF-7B cells were pretreated for 30 minutes with either DMSO or 2µM 
RITA then treated with 40 J/m2 UV-C for the indicated times.  Whole cell extracts were 
prepared and subjected to western blot analysis using antibodies specific for p53 and β-
tubulin.  (B) Knockdown of Hdm2 restores the ability of UV to induce p53 in MCF-7B cells.  
MCF-7B cells were transfected with either a control siRNA or an siRNA specific for Hdm2.  
48 hours following transfection, cells were treated with 40 J/m2 UV-C for the indicated 
times.  Whole cell extracts were prepared and subjected to western blot analysis using 
antibodies specific for p53, Hdm2 and β-tubulin.  (C) Disruption of the p53-Hdm-2 
interaction restores the ability of UV to induce apoptosis in MCF-7B cells.  MCF-7 and 
MCF-7B cells were left untreated, treated with 40 J/m2 UV-C or treated with 40 J/m2 UV-C 
plus 2 µM RITA.  18 hrs following treatment, apoptosis was measured by flow cytometric 
analysis of Annexin-V staining.  
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Supplemental Figure 1.1 
 
The anti-apoptotic effects of Bcl-3 are specific for p53-dependent inducers of apoptosis. 
(A) Staurosporine induces similar levels of apoptosis in both MCF-7 and MCF-7B cells. 
MCF-7 and MCF-7B cells were treated with DMSO or a 100 nM, 500 nM or 2 µM dose of 
Staurosporine. 24 hrs following treatment, apoptosis was measured by flow cytometric 
analysis of Annexin-V staining. (B) Loss of Bcl-3 sensitizes MEFs to UV-induced, but not 
TNFα-induced apoptosis. Bcl-3 +/+ and Bcl-3 -/- mouse embryo fibroblasts were left 
untreated, treated with 40 J/m2 UV-C or treated with 10 ng/ml TNFα. 24 hrs following 
treatment, apoptosis was measured by flow cytometric analysis of Annexin-V staining. 
 62
 
 
 63
Supplemental Figure 1.2 
 
MCF-7B cells exhibit higher NF-κB binding and increased promoter activity at the 
Hdm-2 P2 promoter.  (A) A putative NF-κB site in the Hdm2/Mdm2 promoter.  Promoter 
analysis reveals a potential NF-κB binding site 275 bp upstream of the exon 2 start site in the 
Hdm2 P2 promoter.  The sequence is aligned to the NF-κB consensus sequence and the 
corresponding site in the mouse Mdm2 promoter.  (B) Increased NF-κB binding to a DNA 
probe corresponding to the NF-κB site in the Hdm2 P2 promoter.  Nuclear extracts were 
prepared from MCF-7 and MCF-7B cells and incubated with a 32P labeled double stranded 
oligonucleotide probe corresponding to the putative NF-κB site in the P2 promoter region.  
The complexes were run on a non-denaturing gel and visualized by autoradiography.  The 
experiment was repeated in MCF-7B cells with the addition of antibodies against p65, p52 
and p50 to identify the subunits present in the bound complexes.  (C) MCF-7B cells exhibit 
increased promoter activity from Hdm-2 P2 promoter constructs that include the region 
containing the NF-κB binding site.  50 ng each of three Hdm2 P2 promoter constructs 
containing the indicated portions of the P2 promoter were transfected into MCF-7 and MCF-
7B along with 5ng of renilla luciferase.    Firefly luciferase activity was measured and 
normalized to renilla luciferase.  Values represent fold increase over basal activity (lane 1). 
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Supplemental Figure 1.3 
 
siRNA-mediated knockdown of Hdm2 partially restores the apoptotic response to UV 
in MCF-7B cells.  Knockdown of Hdm2 restores the ability of UV to induce apoptosis in 
MCF-7B cells. MCF-7B cells were transfected with either a control siRNA or an siRNA 
specific for Hdm2. 48 hours following transfection, cells were treated with 40 J/m2 UVC for 
the indicated times. 24 hrs following UV treatment, apoptosis was measured by flow 
cytometric analysis of Annexin-V staining. 
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Experimental Procedures: 
 
Cell Culture 
Primary murine embryo fibroblasts were isolated from day 13 embryos and grown in 
DMEM supplemented with 10% FBS (Sigma) and 1X penicillin/streptomycin (Gibco).  
MCF-7 cells (ATCC) were grown in MEMα supplemented with 10% FBS, 10 ug/ml Insulin 
(Gibco), 1mM Sodium Pyruvate (Gibco) and 1X penicillin/streptomycin.  Karpas 299 cells 
(DSMZ, Braunschweig, Germany) were grown in RPMI supplemented with 10% fetal 
bovine serum and 1X penicillin/streptomycin.  HT1080 cells (ATCC) were grown in DMEM 
supplemented with 10% FBS and 1X penicillin/streptomycin.  U-2OS cells (ATCC) were 
grown in McCoys 5A supplemented with 15% fetal bovine serum and 1X 
penicillin/streptomycin.   MCF-7B cells were generated by transfecting the expression 
construct pFlag-Bcl-3 into MCF-7 cells. Stable clones were generated in medium containing 
1 µg/ml puromycin (Sigma). Clones were verified by Western blotting with a Bcl-3-specific 
antibody.  Cisplatin (Sigma) was resuspended in DMSO and stored at –20°C.  RITA was 
resuspended in DMSO to a concentration of 10mM and stored in the dark at –20°C.  
Pifithrin-α (A.G. Scientific) was resuspended in DMSO to a concentration of 10mM and 
stored in the dark at –20°C.  For UV treatments, cells were placed under a UV lamp and 
dosage was measured with a UV-X radiometer (Ultra Violet Products, Upland, CA). 
 
Antibodies   
For western blots, ChIP analysis and supershift analysis we used antibodies against 
p53 (FL393, Santa Cruz), Bcl-3 (Upstate), Hdm2 (Ab-1, Calbiochem), mdm2 (2A10, from 
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A. Levine), flag (M2, sigma), p65 (5192, Rockland), p52 (From N. Rice), p50 (H-119, Santa 
Cruz) and β-tubulin (H-235, Santa Cruz).  HRP-conjugated anti-mouse and anti-rabbit IgG 
secondary antibodies were from Promega. 
 
Western Blot 
Typically, cells were plated in a 100 mm or 6-well tissue culture dish and treated as 
indicated.  After the indicated timepoints, cells were wash with PBS and lysed in modified 
RIPA buffer (1% NP40, 20mM Tris, 137 mM NaCl, 10% glycerol, 2mM EDTA, 2 µg/mL 
aprotinin, 2 µg/mL leupeptin, 1 mM PMSF).  10 or 15 µg protein were loaded onto 4-12% 
Bis-Tris gels (Invitrogen).  After electrophoresis, gels were transferred to nitrocellulose 
(Biorad) and blocked for 1 hr in TBS containing 0.5% Tween-20, 4% milk and 1% BSA.  
Primary and secondary antibody incubations were performed in blocking buffer at 4°C 
(primary) or room temp (secondary). 
 
Apoptosis Detection 
Cells were plated in 100mm dishes and treated with the indicated dose of UV or 
cisplatin.  At the indicated timepoints, cells were washed with PBS and collected by 
trypsinization.  Cells were washed again in PBS and resuspended in 100 µL annexin binding 
buffer (10mM HEPES, 140mM NaCl, 2.5mM CaCl2, pH 7.4)) containing 5 µL Alexa-488 
conjugated Annexin-V (Molecular Probes) plus 1 µg/ml propidium iodide (Sigma).   Cells 
were incubated for 15 minutes at room temperature and then analyzed on a Facscalibur 
(Becton Dickinson).  Apoptotic cells were measured as positive for Annexin-V staining but 
negative for propidium iodide.  
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Plasmid Constructs 
pCMV2-flag Bcl-3 (Westerheide et al. 2001),  pCMV-flag-p53 (Zhang et al. 1998), 
pg-13-luciferase (el-Deiry et al. 1993) and Hdm2-Luc01, Hdm2-Luc02, and Hdm2-Luc03 
(Phelps et al. 2003) were described previously. 
 
ChIP Assay 
ChIP analysis was performed using a chromatin immunoprecipitation kit (Upstate 
Biotechnology) and a modified version of the manufacturers protocol. Following the 
indicated treatment, cells were fixed for 5 minutes in 1% formaldehyde, washed with PBS 
and lysed for 10 min in lysis buffer. Chromatin was sheared by sonication to an average size 
of approximately 1 kilobase and pre-cleared for 2 h at 4 °C with salmon sperm DNA-
saturated protein G Sepharose beads. Chromatin solutions were precipitated overnight at 4°C 
using 10 µl of the indicated antibodies. Immune complexes were collected with salmon 
sperm DNA-saturated protein G Sepharose beads for 1 h and washed extensively following 
the manufacturer's protocol. Input and immunoprecipitated chromatin were incubated at 
65 °C overnight to reverse crosslinks. After proteinase K digestion, DNA was extracted with 
phenol/chloroform and precipitated with ethanol. Precipitated DNAs were analysed by Real 
Time PCR on an ABI 7100 using SYBR green master mix (ABI).  Each sample was 
normalized to input using the 2-∆∆C(T) method (Livak and Schmittgen 2001).  Hdm2 P2 
promoter specific primers used were: 5’-GAGGTCCGGATGATCGCAGG-3’ and 5’-
 70
GTGGCGTGCGTCCGTGCCCA-3’ and β-Actin promoter specific primers used were 5’-
CCTCCTCCTTCTTCCTCAATCT-3’ and 5’-GGGGAGAGGGGAGGAAA-3’. 
 
Luciferase Assays 
Typically, cells were plated in 24-well dishes and allowed to grow to ~70% 
confluency.  Cells were transfected with the indicated plasmids using polyfect reagent 
(Qiagen) following the manufacturers protocol.  48 hours post-transfection, extracts were 
prepared using the Dual Luciferase Assay System (Promega, Madison, WI) following the 
manufacturers protocol and luciferase activity was measured on an LMax luminometer 
(Molecular Devices, Sunnyvale, CA).  
 
Real Time PCR 
Cells were plated in 100 mm dishes and treated with the indicated doses of UV or 
cisplatin.  At the indicated timepoints, cells were washed in PBS, lysed in Trizol Reagent 
(Invitrogen) and RNA was collected following the manufacturers protocol.  cDNA was 
generated using the M-MLV reverse transcriptase kit (Invitrogen) and quantitative PCR was 
performed on an ABI Prism 7000 (Applied Biosystems, Foster City, CA) using gene specific 
TAQman primer/probe sets (Applied Biosystems). 
 
RNAi 
Synthetic dsRNA oligonucleotides targeting Bcl-3 and Hdm-2 were purchased from 
Xeragon and Ambion, respectively.  The targeted sequence for Bcl-3 is 5’-
AATGGTCTTCTCTCCGCATCA-3’.  Cells were plated in 6-well dishes and allowed to 
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grow to ~70% confluency.  Transfection of the gene specific siRNA plus a control siRNA 
(Ambion) was performed using the transmessenger transfection reagent (Ambion) according 
to the manufacturers protocol.  48 hours post-transfection, cells were treated for the indicated 
time points, lysed and western analysis was performed as described. 
 
Electrophoretic Mobility Shift Assay (EMSA)   
Nuclear and cytoplasmic extracts were obtained from MCF-7 and MCF-7B cells, and 
gel shift analysis was performed as previously described (Mayo et al. 1997b).  Briefly, an 
oligonucleotide corresponding to the putative NF-κB site in the Hdm2 P2 promoter (5’-
GGTGGTTCGGAGGTCTCCGCGGGAGT-3’) was radiolabeled using [α-32P]dCTP 
(Perkin Elmer).  The probe was incubated with 4µg of nuclear extract and 0.1µg/µl poly dIdC 
in DNA binding buffer (50mM NaCl, 10mM Tris pH7.6, 10% glycerol, 1mM DTT, 0.5mM 
EDTA) for 15 minutes at room temperature.  For antibody supershift analysis, extracts were 
preincubated for 15 minutes at room temperature with 1 µg of antiserum before the addition 
of the radiolabeled gel shift probe.   Reactions were separated using non-denaturing PAGE 
and visualized by autoradiography. 
  
 
Chapter II 
 
 
 
Primary Human Hepatocellular Carcinomas Exhibit High 
Levels of Nuclear Bcl-3 Expression. 
 
 
 
Contributions to this chapter were made by Bert O’Neil, Petra Bůžková, 
Hillary Farrah, Hanna Kelly and Bill Funkhouser. 
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Abstract 
 
The transcription factor NF-κB has been shown to be activated in hepatocellular 
carcinoma (HCC), but how it contributes to the oncogenic process is not clear. Recently, 
studies have identified the IκB family member Bcl-3 as a possible mediator of NF-κB 
activation in other inflammation-associated cancers. We set out to determine whether high 
levels of Bcl-3 are characteristic of HCC.  Further, we sought whether Bcl-3 expression is 
associated with particular NF-κB subunit activation and whether expression of Bcl-3 
correlates with expression of the Bcl-3 target genes cyclin D1 and Hdm2 in HCC. Archived 
HCCs from 30 patients were evaluated by immunohistochemistry for all NF-κB subunits, 
Bcl-3, Hdm2, cyclin D1, Bcl-xL and p53. Also, frozen tissue that was available was analyzed 
by western blot for expression of Bcl-3, Hdm2, and p65. Results were correlated with 
clinico-pathologic features. We find that the p50 and p52 NF-κB subunits were frequently 
localized to tumor cell nuclei, indicative of activation (40% and 48%, respectively), whereas 
p65 expression was infrequent. Also, high levels of nuclear Bcl-3 were found in the majority 
of cases (90%) and p52 expression was strongly correlated with Bcl-3 expression. While Bcl-
3 expression did not correlate with either mdm2 or cyclin D1 expression as measured by 
immunohistochemistry, there was a positive correlation between Bcl-3 expression and mdm2 
expression in the limited number of samples available for western blot analysis, suggesting 
that further investigation of the mechanisms of Bcl-3 activation and the role of this activation 
in hepatocarcinogenesis are warranted. 
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Introduction 
 
Hepatocellular carcinoma is a common killer worldwide, with increasing incidence in 
the United States caused by large numbers of both recognized and unrecognized cases of 
hepatitis C virus infection (Davila et al. 2004).  The discovery of effective therapies for HCC 
is an urgent priority, but is hampered by our limited understanding of the molecular 
pathogenesis of HCC.  A growing body of literature has implicated the transcription factor 
NF-κB in hepatocarcinogenesis (Tai et al. 2000a; Tai et al. 2000b; Chiao et al. 2002; Liu et 
al. 2002; Wang et al. 2003; Waris et al. 2003; Cavin et al. 2004; Chan et al. 2004; Girard et 
al. 2004).  The NF-κB family of transcription factors is comprised of five subunits, 
p65/RelA, p50, p52, RelB and c-rel that homo- or heterodimerize to form active 
transcriptional complexes (Baldwin 2001).  The function of the various NF-κB subunits with 
regards to neoplasia remains an active field of investigation.  NF-κB is expressed 
ubiquitously, but sequestered in the cytoplasm by inhibitory protein IκB.  IκB family 
members include IκBα, IκBβ, IκBε and the atypical IκB protein Bcl-3 (Ghosh and Karin 
2002).  Activation of NF-κB involves IκB kinase (IKK)-mediated phosphorylation of IκBα 
on serines 32 and 36 followed by ubiquitination and subsequent proteasomal degradation, 
resulting in the release of NF-κB and its translocation to the nucleus.  There, NF-κB 
mediates the transcription of a wide variety of target genes, including potent anti-apoptotic 
effector proteins such as Bcl-xL (Khoshnan et al. 2000), TRAFs, IAPs (Wang et al. 1998) 
and others.  
The most abundant and widely studied NF-κB dimer is the p50/p65 heterodimer.  
Strong rationale for investigating the role of p50/p65 heterodimers in human HCC is 
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provided by a recent study in an mdr2 knockout mouse model in which loss of mdr2 results 
in a phenotype of peri-portal inflammation that in turn results in multiple peri-portal HCCs 
(Balkwill and Coussens 2004; Pikarsky et al. 2004).  In this model, inflammation (and 
presumably resultant TNF-α secretion) results in activation of p50/p65 heterodimers in 
hepatocytes adjacent to inflamed portal areas.  Specific blockade of NF-κB effected by 
crossing the mdr2 knockout mouse with a mouse expressing a dominant-negative IκBα 
abrogated formation of hepatocellular tumors in this model.  This implicates NF-κB 
activation as an important initiating event in hepatocarcinogenesis, and suggests a potential 
preventative role of NF-κB inhibition for patients with chronic hepatitis.  Several studies of 
NF-κB in HCC cell lines (Tai et al. 2000b; Chiao et al. 2002; Wang et al. 2003) and patients 
with HCC (Tai et al. 2000a) have been reported in which p50 and p65 were detected by 
immunohistochemistry or electromobility shift assay (EMSA), but few if any studies of HCC 
have focused on the other NF-κB subunits.  
More recently, the “atypical” IκB protein Bcl-3 has emerged as a potentially 
important oncogene in several solid tumors, most notably nasopharyngeal cancer and 
endometrial cancer, both of which are mediated by chronic viral infection (Thornburg et al. 
2003; Pallares et al. 2004).  Bcl-3 was first identified as the product of a chromosomal 
translocation in certain lymphomas (McKeithan et al. 1987; Ohno et al. 1990), but little is 
known about its normal physiologic functions outside the immune system, where it seems to 
have a role in several aspects of immune responses (Franzoso et al. 1997; Schwarz et al. 
1997).  Bcl-3, which has a C-terminal transactivation domain, functions as a transcriptional 
co-activator in complex with homodimers of p50 (Fujita et al. 1993), and p52 (Bours et al. 
1993), neither of which has intrinsic trans-activation function. Recently, it was demonstrated 
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that Bcl-3 overexpression occurs in a proportion of human breast cancer samples (Cogswell 
et al. 2000), and subsequently demonstrated that over-expression of Bcl-3 and p52 in breast 
cancer cell lines in vitro leads to increased expression of cyclin D1, suggesting a possible 
oncogenic mechanism (Westerheide et al. 2001).  Also, we previously demonstrated that Bcl-
3 is capable of regulating the expression of mdm2, with resultant inhibition of the pro-
apoptotic function of p53 (Kashatus et al. 2006).  This is a potentially interesting finding with 
regards to hepatocellular carcinoma, as p53 is known to be mutated in only 10-40% of HCCs 
(Murakami et al. 1991; Kubicka et al. 1995; Tannapfel et al. 2000; Anzola et al. 2004). These 
data raise the possibility that Bcl-3 activation in HCC may function as a previously 
unrecognized mechanism of p53 inactivation. 
We undertook the current study with the goal of determining: 1) which NF-κB 
subunits are most frequently active (as measured by nuclear localization) in HCC and 
whether nuclear localization of any individual NF-κB subunits is negatively associated with 
clinical outcome (particularly survival); 2) whether Bcl-3 over-expression and nuclear 
localization are common and relevant in terms of disease characteristics and survival in 
HCC; 3) whether there is correlation between Bcl-3 over-expression and NF-κB subunit 
activation, cyclin D1 expression and/or mdm2 expression.  Our principal hypotheses were 
that tumors with nuclear NF-κB expression would have worse clinical outcomes, and that 
Bcl-3 expression would correlate with p50/p52 activation and with increased expression of 
mdm2 and cyclin D1. 
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Results 
 
Patient characteristics 
The clinical characteristics of the 30 patients whose tumors comprised the tissue 
microarray are summarized in Table 2.1.  Patients with negative serology for hepatitis B and 
C virus were over-represented compared with what would be expected for an unselected 
population of U.S. HCC patients, likely because patients without chronic viral hepatitis are 
more likely to be candidates for partial hepatectomy.  Four of the patients had wedge biopsies 
without attempt at formal resection because of more advanced disease, in some cases 
identified at the time of laparotomy.  One patient who underwent transplant as therapy had 
only tumor tissue available in our pathology archives. These five samples were incorporated 
into the TMA without corresponding adjacent non-neoplastic liver.  At the time of data 
analysis 14 patients were alive, with a median follow-up of 45 months (range 27-84 months).  
16 patients had died, with a median survival of 20 months (range 2-62 months). 
 
Bcl-3 is frequently overexpressed in hepatocellular carcinoma 
In our patient sample, nuclear Bcl-3 staining was observed in 27 of 30 cases of HCC 
(present in ≥ 1+/50% of cells in 15 of the 27 positive cases), compared with only 9/25 
positive (to any degree) in adjacent non-neoplastic liver (Figure 2.2).  The difference in 
staining intensities between tumor and non-tumor samples was highly statistically significant 
(student’s paired t-test p < 0.001), and also comprised an internal negative control as normal 
and tumor cores were mixed on the same TMA slides.  Representative positive and negative 
stains are shown in Figure 2.1.   Because nearly all of the tumors were Bcl-3 positive, there 
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was no detectable association between Bcl-3 expression and survival, nor did we detect an 
association between intensity (on a continuous scale) of Bcl-3 staining and survival (Figure 
2.2).  Cytoplasmic staining was present in most samples, but only nuclear staining was 
scored for purpose of analysis. 
In seven cases, frozen tissue was available in our Tissue Procurement Facility: five 
cases with paired tumor and non-neoplastic liver and two cases with tumor only. Western 
blotting with anti-Bcl-3 antibody confirmed our visual IHC results with the exception of one 
case where the IHC and Western blot results appeared to be discordant (Figure 2.3).  The 
Western blots also confirmed that the antibody was recognizing a protein of the expected 
molecular weight.   
To explore the question of whether Bcl-3 over-expression occurs at the level of 
transcription or protein stability, we assayed the five available pairs of frozen tumor and non-
tumor liver samples (all from patients included in this study) by quantitative PCR.  As shown 
in Figure 2.4, 2/4 of the tumors with Bcl-3 over-expression had equal tumor and normal liver 
Bcl-3 message and the other 2 appeared to over-express message compared with adjacent 
liver.  A larger sample size of frozen tissue would be necessary to resolve whether Bcl-3 
over-expression is more likely to occur at the transcriptional, translational or protein stability 
level.  Search of the ONCOMINETM (Rhodes et al. 2004) microarray database revealed one 
study (Patil et al. 2005) in which gene expression in 104 HCCs was compared with that in 74 
matched non-neoplastic liver samples.  No statistically significant differences in gene 
expression of Bcl-3 were seen, at least by oligonucleotide microarray assay methodology.  In 
fact, there was a trend toward lower Bcl-3 expression in the normal (or cirrhotic) liver tissue. 
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p50 and p52 but not other NF-κB subunits are frequently localized to the nucleus in HCC 
In contradistinction to other reported series of HCC patients in which p65 was 
frequently localized to tumor cell nuclei (a surrogate for activation), we found p65 to be 
visibly present in the nucleus of tumor cells in only 4/30 cases, using both an antibody 
against unmodified p65 and an antibody specific to p65 that has been phosphorylated at 
serine 536.  We also found little evidence of phospho-p65 expression by more sensitive 
Western blotting of whole-cell extracts in seven frozen cases (Figure 2.3), including in cases 
where p50 was over-expressed (data not shown).   p50 and particularly p52 were much more 
frequently visualized in tumor nuclei than other NF-κB subunits.  Staining was less intense 
but also present in matched non-neoplastic liver samples. While there appeared to be 
differences in both frequency and intensity of staining in tumors compared with non-
neoplastic liver (Table 2.2 and Figure 2.2), these differences did not reach statistical 
significance for either p50 or p52 (student’s t test, for p50: p = 0.09, for p52: p = 0.34).  NF-
κB subunits rel-B and cRel were expressed in the nuclei of only one (3%) and none of the 
tumors, respectively.  Interestingly, higher p50 nuclear expression trended strongly toward 
worsening survival, with the HR for death increasing by 8% for every decade increase in IHC 
score (95% CI 1% to 17%, p = 0.075), but the relationship was of borderline statistical 
significance.  Our sample did not have adequate power to detect a statistical correlation 
between p52 nuclear expression level and survival (HR 1.047, 95% CI 0.976, 1.122; p = 0.2). 
 
Cyclin D1 and mdm2 
Two of our hypotheses regarding Bcl-3 were that mdm2 and cyclin D1 would be 
more frequently over-expressed in Bcl-3 expressing tumors.  Mdm2 was over-expressed in 
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the cytoplasm of 7 tumors, and the nuclei of 3 tumors (all of which were also cytoplasm 
positive).  There was no apparent correlation between intensity of Bcl-3 staining and 
positivity for mdm2 by IHC.  Interestingly, the degree of nuclear staining for cyclin D1 was 
actually negatively correlated with Bcl-3 staining intensity (R= -0.28, 95% CI -0.537, -0.071) 
(not shown).  In our limited sample of frozen tumors analyzed by western blotting, there 
appeared to be a strong visible association between strength of bcl-3 expression and strength 
of mdm2 expression (Figure 2.3), suggesting that IHC on paraffin-embedded samples may be 
too insensitive for examining this association compared with western blotting.  More frozen 
samples would be necessary to corroborate this, and we are currently in the process of 
collecting these samples for analysis. 
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Discussion 
 
Hepatocellular carcinoma is an example of a neoplasm that arises in the setting of 
chronic inflammation, a setting in which NF-κB may play a very significant role.  Once 
activated in tumor cells, NF-κB controls the expression of a number of potent inhibitors of 
apoptosis.  The main purpose of this study was to explore the frequency of NF-κB subunit 
nuclear expression in HCC, and whether evidence of activation correlated with patient 
survival.  While our results revealed a trend toward an association between p50 activation 
and survival, our sample size was constrained by tissue availability and thus limited in 
answering this question definitively.  We also set out to determine whether Bcl-3 activation 
was common in HCC based on prior observations in endometrial cancer and nasopharyngeal 
cancer, two virally-mediated malignancies (Thornburg et al. 2003; Pallares et al. 2004).  Our 
study is the first to comprehensively analyze the activation status of all characterized NF-κB 
subunits in human hepatocellular carcinoma.  Our results differ from previously published 
studies in that there is little suggestion in our data that the canonical p50/p65 heterodimer is 
the dominant form of NF-κB expressed in HCC.  What our data do suggest is that HCCs 
nearly always over-express Bcl-3, likely in association with p52 and/or p50 homodimers in 
the nucleus.    Based on the strong trend toward correlation of p50 nuclear localization with 
survival, it is possible that this activity of Bcl-3 and NF-κB is important for initiation and/or 
progression of HCC. 
At present there is relatively little understanding of the regulation of Bcl-3 
expression.  Bcl-3 is degraded by the proteasome upon phosphorylation by GSK-3β in one 
model, which would suggest protein stability as a major determinant of cellular levels of Bcl-
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3 (Viatour et al. 2004).  Very recently, however, a group has published evidence of Bcl-3 
gene amplification in anaplastic large cell lymphoma lines (Mathas et al. 2005).   In our 
limited-sized sample of frozen tumors, we found that 2 of 4 Bcl-3 over-expressing cancers 
had mRNA levels that were no different than that found in the adjacent liver, but in the other 
two cases there appeared to be significantly higher message level.  A much larger sample of 
frozen tissue would be required to study this question in a rigorous manner.  As mentioned 
previously, examination of an oligonucleotide microarray database revealed no evidence of 
Bcl-3 upregulation at the message level when compared with non-neoplastic liver tissues 
from the same patients.  These findings would also tend to support the model that Bcl-3 
levels are more dependent upon protein stability than they are upon transcription.  If it is the 
case that Bcl-3 is regulated by phosphorylation, a more complete understanding of the 
kinases that target Bcl-3 might potentially lead to therapies or preventive therapies for HCC. 
As stated previously, based on a Bcl-3 over-expression model we predicted that 
mdm2 would be over-expressed in concert with Bcl-3.  This did not appear to be the case in 
our group of patients, at least when examining mdm2 expression by immunohistochemistry.  
Of course, regulation of the mdm2/p53 system is exceedingly complex (Vousden and Lu 
2002).  Immunohistochemical measurement of mdm2, therefore, is likely inadequate to 
answer the question of whether Bcl-3 independently regulates mdm2 expression.  Supporting 
this argument, we saw higher expression of mdm2 by western blot in at least one case than 
we did by IHC, suggesting a more sensitive assay than IHC would be necessary to establish a 
link between Bcl-3 and mdm2 protein levels in human tumors.  We found that a large 
fraction of our samples over-expressed nuclear p53 by IHC, a finding which can have a 
number of explanations not limited to mutation (Anzola et al. 2004).  However, if regulation 
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of p53 in HCC were dominated by mdm2 over-expression, we would have expected to see 
lower levels of over-expression of p53 in these samples. 
Cyclin D1 plays an important role in the cell cycle, and is under the control of a large 
number of cellular factors, as evidenced by the fact that the protein was frequently expressed 
in the nuclei of non-neoplastic liver cells in patients who mostly had underlying 
inflammatory processes.  One of the first described functions of Bcl-3 was the transcriptional 
regulation of cyclin D1 levels (Westerheide et al. 2001).  Our study results do not strongly 
implicate Bcl-3 as a primary driver of cyclin D1 expression, and in fact uncovered a negative 
association between Bcl-3 and cyclin D1 expression in our sample of HCC patients. 
In summary, in this set of experiments we have established that HCCs are 
characterized by nuclear Bcl-3 expression in the vast majority of cases, and that the NF-κB 
family members involved in HCC appear to be p50 and p52.  Due to lack of other subunits, 
and to the fact that p50 and p52 do not heterodimerize with each other, we surmise that in 
HCC, over-expression of Bcl-3 results in recruitment of p50 and p52 homodimers to the 
nucleus.  Our future studies will concentrate on elaborating mechanisms by which Bcl-3 
over-expression might be oncogenic in hepatocytes, and in seeking a link between chronic 
inflammation and the nuclear over-expression of Bcl-3.  An important potential clinical 
implication of this finding is that treatment of HCCs with proteasome inhibitors as a means 
of inhibiting NF-κB might not have the intended consequence if the primary means of 
regulation of NF-κB is via Bcl-3.  In fact, since Bcl-3 is degraded by the proteasome, such 
inhibition could lead to further accumulation with potential for a stronger anti-apoptotic 
signal. 
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Table 2.1 – Patient Characteristics 
 
 
 
 
 
Male sex 19 (63)  
Cirrhosis (cause) 19 (63)  
HCV 7  
HBV 4  
HBV/HCV 1  
ETOH 4  
Auto 2  
PSC 1  
Ascites 5 (17)  
Total Bilirubin (n =29)  1.71 mg/dl (0.2 to 6.1) 
Albumin (n = 27) 3.14 g/dl (1.6 to 4.1) 
Child's class   
B  8  
C  3  
AFP mean (n = 26) 3830 ng/ml (5- 69540) 
AFP median 18 ng/ml  
Tumor #   
one 17  
two to five 10  
> 5 3  
Surgery type  
Biopsy 4  
Resection 16 (3 R1, 2 R2) 
Transplant 10  
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Figure 2.1 
 
 
Representative Immunohistochemistry for Bcl-3 
(A & B) Paired tumor (A) and normal (B) tissues from patient 6 were analyzed on the same 
TMA slide stained simultaneously for expression of Bcl-3.  The average scores across 3 
separate cores were 100 for tumor and 5 for normal tissue.  (C & D)  Paired tumor (C) and 
normal (D) tissues from patient 11 were analyzed on same TMA slide stained simultaneously 
for expression of Bcl-3.  The average scores across 3 separate cores were 160 for tumor and 
53 for normal tissue.  Note the lack of any Bcl-3 staining in endothelial cell nuclei in the 
tumor sample (C).  (E) Tumor tissue from patient 9 (with no paired normal tissue) was 
analyzed for expression of Bcl-3.  The average score across 3 separate cores was 35.  (F) 
Simultaneously stained negative primary antibody control. 
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Figure 2.2 
 
Immunohistochemical analysis of 31 hepatocellular carcinoma tumors. 
The immunostain intensity was sorted by duration of survival (as of April 2005). White 
indicates no expression. Green represents tumors, blue represent adjacent non-neoplastic 
liver. Lightest color represents an IHC “score” of 10-49, medium color represents a score of 
50-99, darkest color represents a score of >100. Gray represents a missing data point. Note 
that intense p50 staining appears to occur preferentially in patients in the upper half, 
representing the shortest survival. (T = tumor, Tc = tumor cytoplasm, N = non-neoplastic, Nc 
= non-neoplastic cytoplasm. Only the nuclear score is represented for p50, p52, Bcl-3, Bcl-
XL, p53 and Ki-67). * indicates that only tumor sample was available (no normal tissue). 
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Pt. OS P50 T p50 N P52 T p52 N Bcl-3 T Bcl3 N Bcl-xL  Tn mdm2 Tc mdm2 Nc p53 T p53 N cyc d1 Tn cyc d1 Nn
5 2
18 4
6 5
15 5
*20 7
3 12
*9 16
25 16
1 20
7 20
*17 21
10 27
24 29
30 30
16 33
11 34
*12 35
28 37
23 38
13 40
*2 43
4 47
8 48
14 49
27 50
22 62
29 62
26 65
19 82
21 84
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Figure 2.3 
 
High levels of Bcl-3 expression in HCC tumor samples 
Western blots were performed on whole cell lysates in five paired and two unpaired cases 
and stained with antibodies against Bcl-3, mdm2, β-tubulin and phospho-p65 (S536).  IHC 
scores for Bcl-3 and mdm2 are shown at bottom for each sample.  There was generally good 
concordance between apparent protein abundance on Western and blinded IHC score. 
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Figure 2.4 
 
High levels of Bcl-3 protein do not necessarily correlate with high levels of mRNA. 
Quantitative RT-PCR was performed on five paired samples of tumor and non-neoplastic 
liver for expression of Bcl-3.  Expression data for each sample are normalized to expression 
of glucuronidase β.  For each pair, expression of Bcl-3 in normal tissue is set at 1 and 
expression in tumor is represented as fold difference to the normal.  Of four tumors that 
overexpressed Bcl-3 by immunohistochemistry and on western blot, 2 showed higher tumor 
expression of mRNA and two did not.  The one tumor in which Bcl-3 was not overexpressed 
demonstrated no evidence of higher expression in tumor compared to the baseline in adjacent 
liver. 
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Experimental Procedures 
 
Antibodies 
 Antibodies used for immunohistochemistry were p50 (p50NLS), p52 (C-5), RelB (C-
19), p65 (F-6), Bcl-3 (H-146), Bcl-XL (H-5) and c-Rel (c-Rel) from Santa Cruz, and p53 
(DO-7) and Bcl-2 (124) from DAKO.  Antibodies used for western blot were p53 (FL393, 
Santa Cruz), Bcl-3 (Upstate), mdm2 (2A10, from A. Levine), phospho-p65 (Upstate), and β-
tubulin (H-235, Santa Cruz). 
 
Tissue Microarray creation 
We identified 30 patients who had undergone resection or wedge biopsy of HCCs 
between 1998 and 2002 in the UNC Cancer Registry.  Clinical data including tumor stage, 
underlying liver disease and survival were abstracted from patient records. 59 sequential 
tumor samples were identified in the UNC Department of Pathology, 30 of which were of 
suitable size and quality for creation of a tissue microarray (TMA).  A TMA was created 
using triplicate cores of fixed and paraffin-embedded tumors and adjacent non-neoplastic 
liver (available in 25 of the 30 cases) which were cored with a 1 mm needle and inserted into 
a recipient paraffin block (Beecher Instruments, Sun Prairie, WI).  Samples from the same 
tumor were staggered in the array and a map created for later identification of the identity of 
individual cores.   
Clinical data was abstracted from UNC medical records and outside records under a 
HIPAA-compliant, IRB-approved protocol.  Because time of disease recurrence was not 
always available (e.g. patients had followed up out of the area), only overall survival was 
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recorded.  All survival data were censored as of the last time of survival data collection in 
April 2005. 
 
Immunohistochemical staining 
Unstained 5 micron thick sections were baked at 60º C for 15 min to 1 hour.  Baked 
sections were soaked twice in fresh xylene for 5 min each, then soaked in 100% ethanol for 3 
min, then blocked for endogenous peroxidase with 3% hydrogen peroxide in methanol for 10 
min.  Slides were then soaked in 95% ethanol for 3 min, soaked in 70% ethanol for 3 min, 
rinsed in distilled water, and soaked in Dako wash buffer (Dako, cat. no. S3006) for 5 min.   
Slides were then steamed in a Black & Decker steamer for 25 minutes using antigen retrieval 
buffers (Dako) for each primary antibody to be studied, and then allowed to cool for at least 
20 minutes. Sections were transferred to Dako wash buffer for 5 min.  The TMA was circled 
using a PAP pen (Zymed).  Endogenous biotin was neutralized by incubating the slides in a 
biotin blocking system (Dako X0590) for 10 min at RT in each of the two solutions.  
Sections were then exposed to the primary antibodies at the titers specified in Table 1 for 30 
min at RT. After rinsing in Dako wash buffer, slides were incubated with the Dako LSAB2 
biotinylated link for 10 minutes at RT, rinsed in Dako wash buffer, and then incubated with 
the Dako LSAB2 streptavidin-HRP for 10 minutes at RT.  After again rinsing in Dako wash 
buffer, detection of the antibody/antigen complex was visualized using 3-3' 
diaminobenzidine (DAB) for 5 min. Slides were then rinsed in water, lightly counterstained 
in filtered Mayer's hematoxylin, rinsed, dehydrated, cleared, and mounted.  The cells of 
interest in each core were scored for percentage reactivity and signal strength in both the 
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cytoplasm and the nuclei.  Simultaneously stained normal (non-cirrhotic) liver served as a 
negative control in each experiment. 
 
Scoring of TMAs 
One surgical pathologist blinded to clinical information scored all TMA cores 
reporting the most intense staining seen in a given core on an intensity scale of 0 to 3+, then 
estimated the percentage of cells that were positive (to any degree).  Nuclear and cytoplasmic 
scores were reported separately.  For NF-κB subunits, Bcl-XL, and Bcl-3, only nuclear scores 
were used for analysis.  Triplicate cores were staggered in the TMA to reduce the chance of 
bias.  A second surgical pathologist, also blinded to clinical data, reviewed all cores to 
confirm tumor versus normal/cirrhotic liver.  For the determination of final scores, if three 
samples were evaluable (occasional cores will loosen and come off the slides creating 
missing data points, or necrotic tissue will be present in the majority of a core), the scores 
were averaged, rounding intensity to the nearest whole number and percent positive to the 
nearest whole number.  If two cores were considered positive (1+ or greater/any %) and one 
core negative (0+), the negative value was thrown out.  If only two cores were evaluable, the 
negative core was averaged with the positive core.  
Western Blot Analysis 
Western blot analysis was performed by preparing whole cell extracts and then 
separating 30 to 50 µg of total protein by SDS-PAGE. After transferring the separated 
proteins to nitrocellulose, blots were blocked in Tris-buffered saline-Tween (TBST) with 5% 
milk and then were incubated in primary antibody for either 1 to 2 hours at room temperature 
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or overnight at 4°C. The membranes were then washed in TBST and were incubated for 1 
hour in antirabbit horseradish peroxidase-conjugated secondary antibody (Promega, Madison, 
WI) and were washed again. Protein bands were visualized with enhanced 
chemiluminescence detection (Amersham Life Science).  
Quantitative real-time PCR 
Total RNA was isolated with Trizol (Invitrogen) according to the manufacturer’s 
protocol. Two µg of RNA was reverse transcribed with random hexamers and MMLV-RT 
(Invitrogen) according to the manufacturer’s protocol.  Total RNA was then diluted 1:5 and 
was used for quantitative PCR. Bcl-3 and Glucuronidase-β-specific TAQman primer/probe 
sets were ordered from Applied Biosystems (Foster City, CA). Each PCR reaction contained 
1 µL of cDNA, 1 µL of primer/probe, and 10 µL 2X ABI TAQman master mix in a 20-µL 
total volume. PCR was performed in an ABI Prism 7900 sequence detection system (Applied 
Biosystems). All of the reactions were performed in triplicate and Bcl-3 levels were 
normalized to the number of copies of Glucuronidase-β detected in each sample.  
Statistical Analysis 
For the purpose of statistical analysis, IHC scores were converted to a single 
“intensity score” by multiplying maximum intensity (0 -3 +) times percent of cells positive 
(to any degree) with a possible range of 0 - 300 units possible.  Scores of 10 or more were 
considered positive for purposes of analysis when a dichotomous variable was necessary.  
Wherever possible, the continuous variable was used.  Cox proportional hazard models were 
used for comparisons of IHC scores and survival data.  Associations between immunostains 
were estimated and tested using a nonparametric Kendall correlation.  A student’s t-test was 
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used for comparisons of staining intensities between neoplastic and non-neoplastic tissue 
samples.  The reported p-values are two-sided and not adjusted for multiple testing that 
would preserve the overall type I error. 
  
CONCLUSIONS 
 The role of Bcl-3 in normal and pathological cellular processes is becoming 
increasingly apparent as more is learned about its cellular function.  In these studies, I set out 
to determine the biological function of Bcl-3 as it pertains to the cellular response to DNA 
damage and to investigate its potential function in hepatocellular carcinoma.  I have 
identified Bcl-3 as a critical inhibitor of p53 function downstream of genotoxic stress, a 
finding that sheds light on its potential oncogenic function and provides a new model for its 
role in B-cell development.  In addition, I show that disregulated Bcl-3 expression is 
characteristic of hepatocellular carcinoma. 
 While the presence of high levels of Bcl-3 in certain hematopoietic malignancies was 
established early on, it is becoming increasingly clear that Bcl-3 expression is characteristic 
of a much wider range of human tumors (McKeithan et al. 1987; Ohno et al. 1990; Cogswell 
et al. 2000; Thornburg et al. 2003; Pallares et al. 2004).  However, how high levels of Bcl-3 
contribute to these malignancies, if at all, has remained a mystery.  A member of the IκB 
family, Bcl-3 preferentially binds to p50 and p52 homodimers, and through interactions with 
co-activators and repressors, can induce or inhibit expression of a number of target genes 
(Bours et al. 1993; Nolan et al. 1993; Na et al. 1999).  Presumably, the oncogenic functions 
of Bcl-3 are mediated through its control of transcription.  As such, a number of putative Bcl-
3 target genes have been identified that can be considered candidate effectors of its 
oncogenic function. 
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 Cyclin D1 is an important cell cycle regulatory protein that binds to and activates the 
cyclin dependent kinases CDK4 and CDK6 to promote the G1 to S transition.  Expression of 
Bcl-3, along with p52, has been shown to induce expression of cyclin D1 and to promote cell 
cycle entry in cultured cells (Westerheide et al. 2001).  It has been further shown that loss of 
Bcl-3 protein leads to an increased interaction of HDAC1 and p52 at the cyclin D1 promoter 
and subsequent inhibition of cyclin D1 transcription (Rocha et al. 2003).   A potent 
oncogene, cyclin D1 is an attractive candidate effector of Bcl-3.  Cyclin D1 has been shown 
to be important for breast cancer, colon cancer, lymphoma, melanoma and prostate cancers, 
among others (Fu et al. 2004), and aberrant Bcl-3 expression may contribute to its activity in 
some of these cases. 
Bcl-2 is another target of Bcl-3 with potential oncogenic function.  It was recently 
shown that Bcl-3, in complex with p52 homodimers, directly activates Bcl-2 transcription in 
breast cancer cells (Viatour et al. 2003).  A potent inhibitor of apoptosis, Bcl-2 expression is 
characteristic of a number of malignancies as well as popular target for anti-cancer 
therapeutics (Droin and Green 2004). 
 The finding that Bcl-3 induces mdm2 to inhibit p53 function provides yet another 
important link between Bcl-3 and oncogenesis.  We have found that high levels of Bcl-3 
expression lead to an increase in mdm2 and a subsequent loss of p53 induction following 
DNA damage.  The consequence of this p53 inhibition is protection against DNA damage 
induced apoptosis.  Importantly, loss of Bcl-3 leads to a loss of mdm2 expression and an 
increase in p53 levels following DNA damage induction, leading to an increase in apoptosis. 
 This novel role for Bcl-3 has important implications for cancer development.  All 
cancers must disable p53 in order to progress.  While most cancers have mutations or 
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deletions of p53, many bypass its function through deletion of ARF or upregulation of mdm2 
(Bond et al. 2005).  Our data suggest that the upregulation of Bcl-3 seen in many cancers 
may function to inhibit p53 through the upregulation of mdm2, thus bypassing the need for 
p53 mutation.  This model is supported by the fact that many of the cancers in which Bcl-3 
expression is characteristic, such as hepatocellular carcinoma and nasopharyngeal carcinoma, 
generally exhibit lower percentages of p53 mutations (Spruck et al. 1992; Chang et al. 2002; 
Anzola et al. 2004). 
 Further support of this model will come from more in depth analyses of human tumor 
samples.  Our western blot analysis on the limited hepatocellular carcinoma samples 
available to us revealed a correlation between Bcl-3 over-expression and mdm2 over-
expression.  Analysis of a large number of tumor samples will be necessary to know whether 
those data are significant.  Furthermore, our model would predict that tumors with high levels 
of Bcl-3 should negatively correlate with p53 mutation status.  Extensive p53 mutation 
analysis on a larger tumor set will reveal whether that prediction holds. 
 Our findings also provide novel strategies for combating cancers in which Bcl-3 
expression is high.  While Bcl-3 itself has not traditionally been target for drug discovery, 
and most drugs targeting the NF-κB pathway do not affect Bcl-3 function, a number of drugs 
that are currently in development target the p53-mdm2 interaction in an effort to restore p53 
function to cells in which it has been lost through upregulation of mdm2 or deletion of ARF 
(Issaeva et al. 2004; Vassilev 2004).  Intriguingly, the use of one of these drugs, nutlin-3, has 
recently been shown to be effective in inducing apoptosis in cells derived from B-cell chronic 
lymphocytic leukemia (Coll-Mulet et al. 2006), the cancer from which Bcl-3 was originally 
cloned (McKeithan et al. 1987). 
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The importance of Bcl-3-mediated p53 inhibition for cancer development is clear, but 
how this novel function of Bcl-3 impacts normal physiology is less so.  Early analysis of Bcl-
3 expression patterns showed that its expression is highest in the spleen and liver, suggesting 
a role in immunological function (Nolan et al. 1993).  Intriguingly, further analyses in mouse 
cell lines derived from different stages of B-cell development showed that Bcl-3 expression 
is highest in B-cells just prior to the Ig switch, perhaps indicating a vital role in mediating 
that process (Bhatia et al. 1991).  Further indication of its role comes from the fact that the 
Bcl-3 knockout mice, while developmentally normal, have compromised immune function.  
They are unable to clear L. monocytogenes and are susceptible to infection by S. pneumoniae.  
Additionally, they fail to generate antigen-specific antibodies and have abnormal spleen 
development, including the inability to form germinal centers (Franzoso et al. 1997; Schwarz 
et al. 1997). 
We propose that inhibition of p53 may be a critical function for Bcl-3 in mediating a 
number of processes in immunological development, particularly B-cell maturation.  B-cell 
maturation involves two processes, class switch recombination and somatic hypermutation, 
that are important for generating antibody diversity.  However, these processes generate 
lesions that under different circumstances would be detrimental to the cell and likely elicit a 
DNA damage response (Xu et al. 2005).  The high levels of Bcl-3 expression present in B-
cells just prior to Ig switch will inhibit the p53 response generated by these processes, 
allowing the cells to survive. 
This model presents a number of testable predictions.  For example, if the defect in 
germinal center development seen in the Bcl-3 knockout mice is due to increased p53-
dependent apoptosis, crossing these mice with p53 null animals should rescue the defect.  
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Furthermore, germinal center B-cells isolated from wild-type animals should exhibit higher 
levels of mdm2 expression and lower levels of p53 activity than those from Bcl-3 null mice.  
These studies are currently ongoing in the lab and should reveal whether the model is correct. 
It is interesting to note that this model is similar to one recently proposed for the 
unrelated protein Bcl-6.  Like Bcl-3, Bcl-6 is often translocated in leukemias and lymphomas 
and the Bcl-6 knockout phenotype is remarkably similar to that of Bcl-3 (Ye et al. 1993; Ye 
et al. 1997).  Intriguingly, Bcl-6 has also been shown to inhibit p53 function, but unlike Bcl-
3, it inhibits p53 directly at the levels of transcription.  A recent report concludes that this 
inhibition of p53 is critical to allow germinal center B-cells to undergo somatic 
hypermutation and class switch recombination without eliciting an apoptotic response (Phan 
and Dalla-Favera 2004). 
It has also been shown that expression of Bcl-3 correlates with survival in adjuvant-
induced T-cells (Mitchell et al. 2001).  Activated T-cells require a survival signal following 
antigen stimulation in order to avoid apoptosis and to undergo clonal expansion.  The 
apoptotic signal has been shown to be mediated by the p53 family member p73 (Wan and 
DeGregori 2003).  Given its role in p53 inhibition, Bcl-3 may protect activated T-cells 
through down-regulation of this apoptotic response by inhibiting p73 through a similar 
mechanism.  Supporting this notion, mdm2 has been shown to bind and inhibit p73, although 
not through induction of proteosomal degradation.  Instead, mdm2 disrupts the interaction of 
p73 with critical coactivators and inhibits its ability to promote transcriptional activation 
(Zeng et al. 1999). 
This model also presents testable predictions.  For example, if Bcl-3-mediated mdm2 
induction is critical for T-cell survival, one would predict that an increase in mdm2 levels 
 103
would follow treatment of cells with adjuvant.  Further, knockdown of Bcl-3 in the context of 
T-cell activation should lead to an increase in p73-dependent apoptosis.  Further 
experimentation should clarify these issues. 
Our data also suggest a more general role for Bcl-3 in modulating the p53 response 
given the fact that fibroblasts and other non-hematopoietic cells depend on Bcl-3 for this 
process.  These data support a model in which the levels of Bcl-3 present in a given cell 
determine the extent of the p53 response following DNA damage.  It has been proposed that 
the choice between cell cycle arrest and apoptosis following DNA damage is determined in 
part by the timing of p53 induction because the promoters of the genes mediating these two 
processes have different affinities for p53 (Vousden and Lu 2002).  Bcl-3 may be a critical 
determinant of this decision based on its ability to modulate p53.  As such, cells with 
relatively high Bcl-3 levels will experience a transient p53 response, allowing only for the 
transcription of p53 targets with high affinity binding sites, such as p21.  The result will be a 
transient cell cycle arrest.  Conversely, p53 will remain active longer in cells with relatively 
low levels of Bcl-3, allowing it to induce a wider range of targets, including Noxa, Puma and 
other pro-apoptotic effectors.  Creating a panel of cell lines expressing variable levels of Bcl-
3 should allow us to test this model.  We would predict that as Bcl-3 levels increase, the 
duration of p53 induction will decrease and a lower percentage of cells will undergo 
apoptosis following DNA damage.   
The data presented here, when placed in context of previous work on Bcl-3, support a 
model in which control of p53 is a critical function of Bcl-3 in immune development and 
oncogenesis.  As Bcl-3 expression is found in an ever-growing list of human malignancies, it 
is imperative that we continue to uncover the details of its cellular function.  This work has 
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answered a number of questions about Bcl-3, but has revealed many more.  When these new 
questions are answered, we will be left with a clearer picture of Bcl-3 and hopefully be able 
to use this knowledge to combat disease. 
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